<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Mol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">902</journal-id><journal-id journal-id-type="pmc-domain">molther</journal-id><journal-title-group><journal-title>Molecular Therapy</journal-title></journal-title-group><issn pub-type="ppub">1525-0016</issn><issn pub-type="epub">1525-0024</issn><publisher><publisher-name>American Society of Gene &amp; Cell Therapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11489562</article-id><article-id pub-id-type="pmcid-ver">PMC11489562.1</article-id><article-id pub-id-type="pmcaid">11489562</article-id><article-id pub-id-type="pmcaiid">11489562</article-id><article-id pub-id-type="pmid">39044426</article-id><article-id pub-id-type="doi">10.1016/j.ymthe.2024.07.016</article-id><article-id pub-id-type="pii">S1525-0016(24)00471-4</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Vrellaku</surname><given-names initials="B">Besarte</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn2" ref-type="fn">11</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Sethw Hassan</surname><given-names initials="I">Ilda</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn2" ref-type="fn">11</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Howitt</surname><given-names initials="R">Rebecca</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="fn2" ref-type="fn">11</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Webster</surname><given-names initials="CP">Christopher P.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Harriss</surname><given-names initials="E">Eli</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>McBlane</surname><given-names initials="F">Fraser</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Betts</surname><given-names initials="C">Corinne</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Schettini</surname><given-names initials="J">Jorge</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Lion</surname><given-names initials="M">Mattia</given-names></name><xref rid="aff6" ref-type="aff">6</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Mindur</surname><given-names initials="JE">John E.</given-names></name><xref rid="aff6" ref-type="aff">6</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Duerr</surname><given-names initials="M">Michael</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Shaw</surname><given-names initials="PJ">Pamela J.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Kirby</surname><given-names initials="J">Janine</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Azzouz</surname><given-names initials="M">Mimoun</given-names></name><email>m.azzouz@sheffield.ac.uk</email><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff8" ref-type="aff">8</xref><xref rid="fn1" ref-type="fn">10</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Servais</surname><given-names initials="L">Laurent</given-names></name><email>laurent.servais@paediatrics.ox.ac.uk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff9" ref-type="aff">9</xref><xref rid="fn1" ref-type="fn">10</xref><xref rid="cor2" ref-type="corresp">&#8727;&#8727;</xref></contrib><aff id="aff1"><label>1</label>Department of Paediatrics, MDUK Oxford Neuromuscular Centre &amp; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK</aff><aff id="aff2"><label>2</label>Sheffield Institute for Translational Neuroscience, Division of Neuroscience, School of Medicine and Population Health, University of Sheffield, Sheffield, UK</aff><aff id="aff3"><label>3</label>The Queen&#8217;s College, University of Oxford, Oxford, UK</aff><aff id="aff4"><label>4</label>Bodleian Health Care Libraries, University of Oxford, Oxford, UK</aff><aff id="aff5"><label>5</label>Novartis Pharma AG, Basel, Switzerland</aff><aff id="aff6"><label>6</label>Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA</aff><aff id="aff7"><label>7</label>Bayer Aktiengesellschaft, CGT&amp;Rare Diseases, Leverkusen, Deutschland</aff><aff id="aff8"><label>8</label>Gene Therapy Innovation &amp; Manufacturing Centre (GTIMC), University of Sheffield, Sheffield, UK</aff><aff id="aff9"><label>9</label>Division of Child Neurology, Department of Paediatrics, Centre de R&#233;f&#233;rence des Maladies Neuromusculaires, University Hospital Li&#232;ge and University of Li&#232;ge, Li&#232;ge, Belgium</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author: Mimoun Azzouz, Sheffield Institute for Translational Neuroscience, Division of Neuroscience, School of Medicine and Population Health, University of Sheffield, Sheffield, UK. <email>m.azzouz@sheffield.ac.uk</email></corresp><corresp id="cor2"><label>&#8727;&#8727;</label>Corresponding author: Laurent Servais, Department of Paediatrics, MDUK Oxford Neuromuscular Centre &amp; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. <email>laurent.servais@paediatrics.ox.ac.uk</email></corresp><fn id="fn1"><label>10</label><p id="ntpara0010">These authors contributed equally</p></fn><fn id="fn2"><label>11</label><p id="ntpara0015">These authors contributed equally</p></fn></author-notes><pub-date pub-type="ppub"><day>02</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>22</day><month>7</month><year>2024</year></pub-date><volume>32</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">473117</issue-id><fpage>3220</fpage><lpage>3259</lpage><pub-history><event event-type="pmc-release"><date><day>22</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>19</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-20 00:25:16.143"><day>20</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>The emergence of adeno-associated virus (AAV)-based gene therapy has brought hope to patients with severe monogenic disorders. However, immune responses to AAV vectors and transgene products present challenges that require effective immunosuppressive strategies. This systematic review focuses on the immunosuppressive protocols used in 38 clinical trials and 35 real-world studies, considering a range of monogenic diseases, AAV serotypes, and administration routes. The review underscores the need for a deeper understanding of immunosuppressive regimens to enhance the safety and effectiveness of AAV-based gene therapy. Characterizing the immunological responses associated with various gene therapy treatments is crucial for optimizing treatment protocols and ensuring the safety and efficacy of forthcoming gene therapy interventions. Further research and understanding of the impact of immunosuppression on disease, therapy, and route of administration will contribute to the development of more effective and safer gene therapy approaches in the future.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fx1.jpg"/></fig></abstract><abstract abstract-type="teaser" id="abs0020"><p>Through a systematic literature review, Vrellaku and colleagues emphasize the importance of minimizing immunological responses to optimize AAV gene therapy protocols. Their findings underscore the need for further research of the impact on immunosuppression on disease and therapy administration, aiming to develop safer and more effective AAV gene therapy protocols.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>adeno-associated virus, AAV</kwd><kwd>gene therapy</kwd><kwd>immunosuppression protocols</kwd><kwd>immunosuppressant</kwd><kwd>immunity</kwd><kwd>monogenic disorders</kwd><kwd>clinical trials</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Gene therapy clinical trials using adenovirus (AdV) or adeno-associated virus (AAVs) as delivery systems have been ongoing since the late 1990s.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> The first phase 1 clinical trial of AdV-based gene therapy in 1996 delivered the cystic fibrosis transmembrane conductance regulator (<italic toggle="yes">CFTR</italic>) gene to patients with cystic fibrosis.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> However, in 1999, gene therapy research was abruptly halted due to the death of Jesse Gelsinger after treatment for ornithine-transcarbamylase (OTC) hepatic enzyme deficiency with AdV-based gene therapy.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> After Gelsinger received an injection of an AdV vector carrying a wild-type version of the OTC enzyme and died soon after, an immediate review was prompted which raised questions regarding the safety profile of viral vectors. It was found that blood samples from Jesse Gelsinger contained high levels of pre-existing antibodies against AdV serotype 5, and that these antibodies were able to enhance innate immune responses (in particular dendritic cells) resulting in such an extreme, and ultimately fatal, inflammatory response.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> This led eventually to the use of AAV rather than AdV. In 2012, alipogene tiparvovec was the first approved AAV-mediated gene therapy in Europe for treating hereditary lipoprotein lipase deficiency using an AAV1 vector.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> After extensive clinical development, in 2017, voretigene neparvovec (VN; AAV2-hRPE65v2) received the U.S. Food and Drug Administration (FDA) approval for pediatric patients with RPE65-associated Leber congenital amaurosis (LCA) and confirmed biallelic RPE65-mediated retinal dystrophy, which are conditions that result in progressive vision loss, making it the first-ever FDA-approved gene therapy.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Similarly, onasemnogene abeparvovec (OA), an AAV serotype 9 (AAV9)-based gene therapy for pediatric patients with spinal muscular atrophy (SMA), was first made available in the United States in 2019 before its approved use in more than 40 countries.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Rapid and early benefits of OA were demonstrated in symptomatic patients with infantile-onset SMA in the phase 3 STR1VE<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> and STR1VE-EU<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> trials, with evidence of sustained and durable efficacy, as well as a favorable long-term safety profile as shown in the 5-year extension of the phase 1 trial, START.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Valoctocogene roxaparvovec and etranacogene dezaparvovec were approved for the treatment of hemophilia A and B in 2023 and 2022, respectively.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Recently, the FDA approved fidancogene elaparvovec for adult patients with moderate to severe hemophilia B. In addition, delandistrogene moxeparvovec-rokl is the first gene therapy approved by the FDA for treatment of Duchenne muscular dystrophy (DMD).<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p><p id="p0015">The transfer of DNA into specific cell types thus constitutes an elegant and attractive approach to target the root cause of disease in individuals who present with a severe genetic condition&#8212;mostly rare and severe monogenic disorders with haploinsufficiency. To date, the vast majority of clinical developments in gene therapy rely on AAVs, primarily for the replacement or addition of genes.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p><p id="p0020">Despite recent successful regulatory approvals, one of the challenges that remains for further successful implementation of AAV-based gene therapies is overcoming immune responses geared toward the vector or transgene. Such immune responses can lead to loss of treatment efficacy over time and can also result in severe and sometimes fatal toxicities in treated patients. Toxicities often manifest as elevated liver enzymes due to the body&#8217;s immune response against the vector components, such as the capsid or expression cassette as well as the transgene product, resulting in liver inflammation and subsequent damage to liver cells, as indicated by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) release. Additionally, patients may experience thrombotic microangiopathy (TMA), including kidney injury, as well as cardiotoxicity.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> Although OA has been delivered in more than 1,800 SMA patients worldwide and demonstrates clear evidence of clinically meaningful efficacy,<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> especially when administered early in young infants,<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> several adverse events (AEs) related to the host immune response and complement activation elicited by AAV capsid proteins have been reported.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> A study reported the first fatal TMA case following administration of OA in a 6-month-old child with SMA type 1<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> who was a carrier of a potential genetic predisposition in the complement factor I gene. The finding of severe TMA is likely due to complement recognition of the AAV capsid following OA therapy, demonstrating the broad impact of systemic AAV on immune activation and the need for dosing protocols to add immunosuppression to avoid these AEs.</p><p id="p0025">Recent strategies to evade detrimental immune responses to AAV exposure include the engineering of AAV by replacing the viral genome with a therapeutic expression cassette containing inverted terminal repeats, promoters and enhancers, and a codon-optimized gene of interest, while also modifying capsid sequences to yield a recombinant AAV (rAAV) that decreases immunogenicity and prolongs transduction in host cells.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> However, the challenge of overcoming host immunity to better enable gene therapy remains. While AAV infection is considered non-pathogenic in humans, initial exposure to AAV induces cellular and humoral immune responses against rAAV due to capsid similarity.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Although AAV has been known to be a non-pathogenic virus, recent reports of cases of acute severe hepatitis in children have challenged the idea that AAV is a harmless virus.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> More specifically, three independent studies published in March 2023 demonstrated that infection with AAV2 was linked to recent clusters of unexplained acute severe hepatitis in children.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref></p><p id="p0030">Roughly 30%&#8211;70% of the general population have pre-existing neutralizing antibodies (NAbs) against various serotypes, including AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9, depending on the geographical location, health status, and assay type, among other factors across studies.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> Immune responses against AAV have also been observed across different monogenic disorders, causing the various adverse reactions described above. In addition, immune responses can sometimes hinder therapeutic effects by eliciting antibodies against AAV capsids, which reduces the expression of the transgene product. This reduction in expression can also occur if transduced cells are killed by cytotoxic T&#160;cells or if there are immune responses against the transgene product itself. Humoral immune responses, measured by different assays as either NAbs and total antibodies (TAbs), can create an immune response barrier to successful AAV transduction.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> NAbs can neutralize capsids, either by interfering with intracellular processes that lead to capsid uncoating or by blocking key epitopes needed for receptor-mediated uptake into target cells, thereby decreasing the efficacy of gene transfer therapy.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Opsonization is another mechanism by which anti-AAV TAbs may impact AAV gene therapy treatment efficacy.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Furthermore, T&#160;cell responses may eliminate transgene-expressing cells, resulting in hepatotoxicity and loss of transgene expression, as seen in several clinical trials.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> As such, the host immune response is an important factor to monitor and temper after gene therapy as it may relate to both the treatment&#8217;s safety and efficacy.</p><p id="p0035">Extensive efforts to suppress immune responses to AAV have been undertaken across trials. Corticosteroids such as methylprednisolone, prednisone, and prednisolone are widely used in immunosuppressive protocols for inhibiting immune responses to AAV by the decrease of&#160;proinflammatory cytokines/chemokines and attenuating liver toxicity.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> Early trials of AAV gene therapy used a reactive approach for administering corticosteroids in response to instances of elevated liver enzymes, which were thought, in certain cases, to be linked to an AAV capsid-specific cytotoxic T&#160;cell response indicative of liver injury.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> Corticosteroid treatment typically resolves the elevation of liver transaminases.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> Subsequent clinical trials incorporated prophylactic immunosuppression regimens that included one or a combination of pharmacotherapies. Corticosteroids bind to glucocorticoid receptors and modify transcriptional signaling that results in global anti-inflammatory and immunosuppressive effects.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> Corticosteroids exert these effects through multiple mechanisms including downregulation of Toll-like receptor expression, suppression of proinflammatory cytokines, and upregulation of anti-inflammatory cytokines.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></p><p id="p0040">Other immunosuppressants used in AAV gene therapies include sirolimus, mycophenolate mofetil, calcineurin inhibitors and rituximab. Mycophenolate mofetil inhibits T and B cell proliferation by targeting type II inosine monophosphate dehydrogenase, thus suppressing both cell-mediated and humoral immune responses.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref><sup>,</sup><xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Sirolimus is also used in AAV clinical trials for immune suppression (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02240407" id="intref0010">NCT02240407</ext-link>) and works by inhibiting T and B cell activation and induces regulatory T&#160;cells (Tregs) through mammalian target of rapamycin (mTOR) targeting.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></p><p id="p0045">Calcineurin inhibitors such as tacrolimus exert their immunosuppressive effects by suppressing the production of proinflammatory cytokines such as IL-2, thereby inhibiting T&#160;cell activation and proliferation and inhibition of T helper cell-dependent B cell response.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><sup>,</sup><xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> AAV clinical trials also use a combination of immunosuppressant therapies, either administered before or at the time of AAV dosing, and these are continued after AAV dosing. The combination of rituximab, sirolimus, and corticosteroids was used in a recent clinical trial for GM2-gangliosidosis through CNS-directed AAV delivery<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> with no vector-related AEs observed. Moreover, patients received glucocorticoids with or without tacrolimus to decrease the risk of vector-related immune responses.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></p><p id="p0050">While the use of immunosuppressive regimens affords some level of control over immune responses to AAV gene therapy, these protocols also come with an increased risk of infection or viral reactivation, especially in patients who may already be in a severe clinical condition. This can question the safety and/or benefit ratio of immunosuppression&#8212;for instance, when low doses of AAV are injected locally or in a well-delineated space. Despite the importance of an adequate immunosuppressive regimen, there is no consensus or specific guidelines on which regimen is the most appropriate in terms of risk versus benefit ratio, either generally or more specifically in regard to AAV dose, serotype, route of administration, and any pre-existing or underlying condition(s). To our knowledge, no formal or informal comparison of the different immunosuppressive regimens has been conducted.</p><p id="p0055">The aim of this review was to systematically catalog the various immunosuppressive protocols used across various AAV gene therapy trials, and to map these according to monogenic disease, gene therapy treatment (including vector serotype), and route of administration. Additionally, clinical trials will be mapped according to serious adverse reactions, including biological biomarkers (e.g., AST, ALT, thrombocytopenia, and lactate dehydrogenase). We also describe methods for treating immune responses and evaluate the efficacy of these protocols.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Study characteristics</title><p id="p0060"><xref rid="tbl1" ref-type="table">Table&#160;1</xref> depicts a summary of the 38 AAV clinical trials assessed in this review. The included studies were mainly conducted in the United States (<italic toggle="yes">n</italic>&#160;= 28), the UK (<italic toggle="yes">n</italic>&#160;= 8), Germany (<italic toggle="yes">n</italic>&#160;= 6), Australia (<italic toggle="yes">n</italic>&#160;= 5), and France (<italic toggle="yes">n</italic>&#160;= 5), with 15 other countries also contributing to these clinical trials (<xref rid="tbl1" ref-type="table">Table&#160;1</xref>). The 38 studies were conducted between 2008 and 2024, but more than 50% of these studies were conducted between 2021 and 2023 (<xref rid="fig1" ref-type="fig">Figure&#160;1</xref>A). Although more than 15 different diseases were included in these clinical trials, the most common were hemophilia B (<italic toggle="yes">n</italic>&#160;= 8), SMA (<italic toggle="yes">n</italic>&#160;= 7), LCA (<italic toggle="yes">n</italic>&#160;= 5), DMD (<italic toggle="yes">n</italic>&#160;=&#160;5), and hemophilia A (<italic toggle="yes">n</italic>&#160;= 3).<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table&#160;1</label><caption><p>Overview of AAV gene therapy clinical trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">No.</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">AAV gene therapy</th><th colspan="1" rowspan="1">No. of participants and age ranges</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">Highest dose</th><th colspan="1" rowspan="1">Vector type</th><th colspan="1" rowspan="1">Immunosuppressive protocol</th><th colspan="1" rowspan="1">Prophylactic or reactive regimen</th><th colspan="1" rowspan="1">Clinical evidence of immunosuppression effectiveness</th><th colspan="1" rowspan="1">NCT (phase)</th><th colspan="1" rowspan="1">Reference</th><th colspan="1" rowspan="1">Country</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">hemophilia A</td><td colspan="1" rowspan="1">valoctocogene roxaparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 134; age range 18&#8211;70 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">6&#160;&#215;&#160;10<sup>13</sup> vg/kg</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">prednisone or prednisolone tapering dose of 60&#160;mg per day for 8&#160;weeks<break/>other immunosuppressants were used by 39 participants (29.1%) because of contraindications, side effects, or a poor or no response to glucocorticoid treatment (budesonide, tacrolimus, mycophenolate, methylprednisolone)</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">reduced ALT levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03370913" id="intref0135">NCT03370913</ext-link> (3)</td><td colspan="1" rowspan="1">Mahlangu et&#160;al., 2023, Ozelo et&#160;al., 2022<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib137" ref-type="bibr"><sup>137</sup></xref></td><td colspan="1" rowspan="1">USA<break/>Australia<break/>Belgium<break/>Brazil<break/>France<break/>Germany<break/>Israel<break/>Italy<break/>Republic of Korea<break/>South Africa<break/>Spain<break/>Taiwan<break/>UK</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">hemophilia A</td><td colspan="1" rowspan="1">valoctocogene roxaparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9 age &gt;18 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">6&#160;&#215;&#160;10<sup>13</sup> vg/kg</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">prednisolone, tapering dose of 60&#160;mg/kg for 2&#160;weeks, then down to 5&#160;mg/day for 1&#160;week</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">reduced ALT levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02576795" id="intref0140">NCT02576795</ext-link> (1/2)</td><td colspan="1" rowspan="1">Rangarajan et&#160;al., 2017, Long et&#160;al., 2021, Fong et&#160;al., 2022, Pasi et&#160;al., 2021<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref><sup>,</sup><xref rid="bib85" ref-type="bibr"><sup>85</sup></xref></td><td colspan="1" rowspan="1">UK</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">hemophilia A</td><td colspan="1" rowspan="1">giroctocogene fitelparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 11 (&#8805;18 years)</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">3&#160;&#215;&#160;10<sup>13</sup> vg/kg</td><td colspan="1" rowspan="1">AAV2/6</td><td colspan="1" rowspan="1">prednisone, 60&#160;mg with dose tapering to 30&#160;mg, 15&#160;mg, and 5&#160;mg/d</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">reduced ALT levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03061201" id="intref0145">NCT03061201</ext-link> (1/2)</td><td colspan="1" rowspan="1">Leavitt et&#160;al., 2024<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">BBM-H901</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10 age &gt;18 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">5&#160;&#215;&#160;10<sup>12</sup> vg/kg</td><td colspan="1" rowspan="1">dsAAV843</td><td colspan="1" rowspan="1">prednisone, 1&#160;mg/kg</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">reduced proportion of cytotoxic T&#160;cells<break/>downregulated percentage of CD16<sup>+</sup> monocytes and dendritic cells</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04135300" id="intref0150">NCT04135300</ext-link> (1)</td><td colspan="1" rowspan="1">Xue et&#160;al., 2022<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref></td><td colspan="1" rowspan="1">China</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">etranacogene dezaparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 54 age &gt;18 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">2.10&#160;&#215;&#160;10<sup>13</sup> vg/kg</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">prednisolone or methylprednisolone or prednisone, starting dose 60&#160;mg with tapering until 5&#160;mg/week</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03569891" id="intref0155">NCT03569891</ext-link> (3)</td><td colspan="1" rowspan="1">Pipe et&#160;al., 2023<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></td><td colspan="1" rowspan="1">USA<break/>Belgium<break/>Denmark<break/>Germany<break/>Ireland<break/>The Netherlands<break/>Sweden<break/>UK</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">verbrinacogene setparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10 age &gt;18 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">1.28&#160;&#215;&#160;10<sup>12</sup> vg/kg</td><td colspan="1" rowspan="1">AAV2/S3</td><td colspan="1" rowspan="1">prednisolone with or without tacrolimus, methylprednisolone at varying doses</td><td colspan="1" rowspan="1">prophylactic and reactive</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03369444" id="intref0160">NCT03369444</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03641703" id="intref0165">NCT03641703</ext-link> (1/2)</td><td colspan="1" rowspan="1">Chowdary et&#160;al., 2022<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></td><td colspan="1" rowspan="1">USA<break/>Ireland<break/>Italy<break/>UK</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">AMT-060</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10 age &gt;18 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">2&#160;&#215;&#160;10<sup>13</sup> gc/kg</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">prednisolone</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">reduced ALT levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02396342" id="intref0170">NCT02396342</ext-link> (1/2)</td><td colspan="1" rowspan="1">Majowicz et&#160;al., 2019, Miesbach et&#160;al., 2018<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref><sup>;</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref></td><td colspan="1" rowspan="1">Denmark<break/>Germany<break/>The Netherlands</td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">SPK-9001</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 15&#160;&#8805; 18 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">2&#160;&#215;&#160;10<sup>12</sup> vg/kg</td><td colspan="1" rowspan="1">a novel, bioengineered single-stranded adeno-associated viral vector carrying human FIX variant</td><td colspan="1" rowspan="1">prednisolone, 60&#160;mg</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">reduced ALT levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02484092" id="intref0175">NCT02484092</ext-link> (1/2)</td><td colspan="1" rowspan="1">George et&#160;al., 2017<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref></td><td colspan="1" rowspan="1">USA<break/>Australia</td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">BAX 335 (scAAV8.FIXR338)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 30 20 to 69 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">3&#160;&#215;&#160;10<sup>12</sup> vg/kg</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">prednisone, 2.6&#8211;60&#160;mg with dose tapering</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">although corticosteroid therapy was associated with immediate normalization of the IFN-&#947; ELISpot in participant 6, this signal remained elevated for weeks after the initiation of prednisone in participant 7<break/>systemic corticosteroid administration initiated in response to ALT elevations in participants 6 and 7, and as prophylaxis in participant 8, did not stabilize FIX activity levels in these participants</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT01687608" id="intref0180">NCT01687608</ext-link> (1/2)</td><td colspan="1" rowspan="1">Konkle et&#160;al., 2021<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">scAAV2/8-LP1-hFIXco</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 14&#160;&#8805; 18 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">2&#160;&#215;&#160;10<sup>12</sup> vg/kg</td><td colspan="1" rowspan="1">scAAV2/8</td><td colspan="1" rowspan="1">prednisolone, 60&#160;mg with dose tapering</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">reduced ALT levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00979238" id="intref0185">NCT00979238</ext-link> (1/2)</td><td colspan="1" rowspan="1">Nathwani et&#160;al., 2011, Nathwani et&#160;al., 2014<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref></td><td colspan="1" rowspan="1">USA<break/>UK</td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">etranacogene dezaparvovec (ATM-061)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3 (ages 43, 47, and 50 years)</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">2&#160;&#215;&#160;10<sup>13</sup> gc/kg</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">prednisone, 50&#160;mg for 5&#160;days starting at day 94 for bronchitis treatment in 1 patient</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03489291" id="intref0190">NCT03489291</ext-link> (2b)</td><td colspan="1" rowspan="1">Von Drygalski et&#160;al., 2019<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">DMD</td><td colspan="1" rowspan="1">rAAV2.5-CMV-minidystrophin (d3990)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6; 5&#8211;11 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">3&#160;&#215;&#160;10<sup>12</sup> vg</td><td colspan="1" rowspan="1">AAV2.5</td><td colspan="1" rowspan="1">methylprednisolone, 2&#160;mg/kg but limited to &lt;1&#160;g in total</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">IFN-&#947; levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00428935" id="intref0195">NCT00428935</ext-link>(1)</td><td colspan="1" rowspan="1">Bowles et&#160;al., 2012<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">DMD</td><td colspan="1" rowspan="1">delandistrogene moxeparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 4; 4 to 7 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">2&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">prednisone, 1&#160;mg/kg with tapering over 30&#160;days</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">liver enzyme elevation returned to normal after corticosteroids</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03375164" id="intref0200">NCT03375164</ext-link> (1 and 2)</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2020<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">DMD</td><td colspan="1" rowspan="1">delandistrogene moxeparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 41; age range 4&#8211;8 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">2&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">prednisone or prednisolone, 1&#160;mg/kg daily</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03769116" id="intref0205">NCT03769116</ext-link> (2)</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2023<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">DMD</td><td colspan="1" rowspan="1">delandistrogene moxeparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 20; age range &#8805;4 to &lt;8 years</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">1.33&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">prednisone or prednisolone, 1&#160;mg/kg daily</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04626674" id="intref0210">NCT04626674</ext-link> (1)</td><td colspan="1" rowspan="1">Zaidman et&#160;al., 2023<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">SMA</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 76; mean age 16.8</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">1&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">prednisolone, 1&#160;mg/kg</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A (observational study)</td><td colspan="1" rowspan="1">Wei&#946; et&#160;al., 2022<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref></td><td colspan="1" rowspan="1">Germany<break/>Austria</td></tr><tr><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">SMA</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 15; median age 32&#160;days (range, 9&#8211;43)</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">1&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">prednisolone, initially 1&#160;mg/kg/day, then increased to 2&#160;mg/kg/day following protocol amendments</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">no SAEs related to gene therapy product</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03505099" id="intref0215">NCT03505099</ext-link> (3)</td><td colspan="1" rowspan="1">Servais et&#160;al., 2023<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref></td><td colspan="1" rowspan="1">USA<break/>Australia<break/>Belgium<break/>Canada<break/>Japan<break/>UK</td></tr><tr><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">SMA</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21; age range, 0.5&#8211;24&#160;months</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">1&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">prednisolone, 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">hypertension</td><td colspan="1" rowspan="1">N/A (cohort study)</td><td colspan="1" rowspan="1">D'Silva et&#160;al., 2022<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref></td><td colspan="1" rowspan="1">Australia</td></tr><tr><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">SMA</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 15 up to 6&#160;months</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">2.4&#160;&#215;&#160;10<sup>14</sup> vg</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">prednisolone, 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">reduced ALT and AST levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02122952" id="intref0220">NCT02122952</ext-link> (1)</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2017<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">SMA</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8 age range 10&#8211;37&#160;months</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">1.1&#160;&#215;&#160;10<sup>14</sup> vg</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">prednisolone, 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">increased transaminases typically responded to steroid treatment</td><td colspan="1" rowspan="1">N/A (retrospective analysis)</td><td colspan="1" rowspan="1">Friese et&#160;al., 2021<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></td><td colspan="1" rowspan="1">Germany</td></tr><tr><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">SMA</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 22 up to 180&#160;days</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">1.1&#160;&#215;&#160;10<sup>14</sup> vg</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">prednisolone, 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">prevented elevation of ALT levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03306277" id="intref0225">NCT03306277</ext-link> (3)</td><td colspan="1" rowspan="1">Day et&#160;al., 2021, Mercuri et&#160;al., 2021<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">X-linked myotubular myopathy</td><td colspan="1" rowspan="1">resamirigene bilparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 26; age range, 10.0&#8211;64.7&#160;months</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1">3.5&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg) daily</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03199469" id="intref0230">NCT03199469</ext-link> (2/3)</td><td colspan="1" rowspan="1">Shieh et&#160;al., 2023<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref></td><td colspan="1" rowspan="1">USA<break/>Canada<break/>France<break/>Germany</td></tr><tr><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">LCA2</td><td colspan="1" rowspan="1">AAV2-hRPE65v2</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 12; &#8805;18 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>11</sup> vg</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">prednisone, 1&#160;mg/kg/day for 10&#160;days, followed by 0.5&#160;mg/kg/day for 7&#160;days</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">reduced NAb levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00516477" id="intref0235">NCT00516477</ext-link> (1)</td><td colspan="1" rowspan="1">Maguire et&#160;al., 2008, Simonelli et&#160;al., 2010<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref>,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">LCA2</td><td colspan="1" rowspan="1">rAAV2-CBSB-hRPE65</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3; ages 21, 23, and 24 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">5.96&#160;&#215;&#160;10<sup>10</sup> vg</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">steroids</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00481546" id="intref0240">NCT00481546</ext-link> (1)</td><td colspan="1" rowspan="1">Hauswirth et&#160;al., 2008<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">LHON</td><td colspan="1" rowspan="1">scAAV2-P1ND4v2</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 28; 16&#8211;56 years</td><td colspan="1" rowspan="1">intravitreal</td><td colspan="1" rowspan="1">1&#160;&#215;&#160;10<sup>10</sup> vg/eye</td><td colspan="1" rowspan="1">scAAV2</td><td colspan="1" rowspan="1">prednisolone</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">management of uveitis</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02161380" id="intref0245">NCT02161380</ext-link> (1)</td><td colspan="1" rowspan="1">Lam et&#160;al., 2022<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">age-related macular degeneration</td><td colspan="1" rowspan="1">rAAV.sFLT-1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 40; &#8805;55 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">1&#160;&#215;&#160;10<sup>11</sup></td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">prednisolone</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT01494805" id="intref0250">NCT01494805</ext-link> (1)</td><td colspan="1" rowspan="1">Rakoczy et&#160;al., 2015<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref></td><td colspan="1" rowspan="1">Australia</td></tr><tr><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">RPE65-deficient LCA and severe early childhood-onset retinal dystrophy</td><td colspan="1" rowspan="1">rAAV2-CB-hRPE65</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 12; 6 to 39 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">6&#160;&#215;&#160;10<sup>11</sup> vg</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">topical corticosteroids</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">postoperative treatment with topical corticosteroids and antibiotics<break/>no enzyme-linked immunospot response to transgene or capsid<break/>no vector DNA in the blood</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00749957" id="intref0255">NCT00749957</ext-link> (1/2)</td><td colspan="1" rowspan="1">Weleber et&#160;al., 2016<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">RPE65-mediated inherited retinal dystrophy (LCA)</td><td colspan="1" rowspan="1">AAV8-coRPGR codon optimized RPGR</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 18; &#8805;18 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">5&#160;&#215;&#160;10<sup>12</sup> vp/mL</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">prednisolone; 1&#160;mg/kg at start of GT; 60&#8211;30&#160;mg/day upon acute inflammation</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">the subretinal inflammation seems to have resolved in all cases by 6&#160;months after a course of oral corticosteroids. The inflammation seemed to have resolved in all cases by 6&#160;months when all patients had creased oral corticosteroid treatment<break/>no patient required secondary immunosuppressive therapy</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03116113" id="intref0260">NCT03116113</ext-link> (1/2)</td><td colspan="1" rowspan="1">Cehajic-Kapetanovic et&#160;al., 2020<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref></td><td colspan="1" rowspan="1">USA<break/>UK</td></tr><tr><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">RPE65-mediated inherited retinal dystrophy (LCA)</td><td colspan="1" rowspan="1">VN (AAV2-hRPE65v2)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 31; 4&#8211;44 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>11</sup> vg</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">prednisone; 1&#160;mg/kg/day, maximum dose 40&#160;mg/day and tapered until 3&#160;days before injection of the second eye when the steroid regimen was repeated</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00999609" id="intref0265">NCT00999609</ext-link> (3)</td><td colspan="1" rowspan="1">Russell et&#160;al., 2017<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">X-linked retinitis pigmentosa</td><td colspan="1" rowspan="1">AAV8-RS1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 11; 23&#8211;72 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">3&#160;&#215;&#160;10<sup>11</sup> vg</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">cyclosporine: 175&#160;mg twice daily; mycophenolate mofetil at 500 and 1,000&#160;mg twice daily; prednisone at 60&#160;mg</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">not efficacious</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02317887" id="intref0270">NCT02317887</ext-link> (1/2)</td><td colspan="1" rowspan="1">Mishra et&#160;al., 2021<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">X-linked retinoschisis</td><td colspan="1" rowspan="1">cotoretigene toliparvovec</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 18; 20.7&#8211;50.7 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">5&#160;&#215;&#160;10<sup>11</sup> vg</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">preoperative treatment: 1&#160;mg/kg/day of prednisolone (beginning 2&#160;days before gene therapy, on the day of surgery and for 7&#160;days afterward) followed by 0.5&#160;mg/kg/day for 7&#160;days, 0.25&#160;mg/kg/day for 2&#160;days, and 0.125&#160;mg/kg/day for 2&#160;days<break/><break/>postoperative (additional) treatment: prednisolone: 60&#160;mg daily with tapering; dexamethasone: 0.1% or 0.7&#160;mg</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">1 case of reduced visual acuity resolved with corticosteroids but 1 case did not as there had been loss of central photoreceptors</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03116113" id="intref0275">NCT03116113</ext-link> (1)</td><td colspan="1" rowspan="1">von Krusenstiern et&#160;al., 2023<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref></td><td colspan="1" rowspan="1">USA<break/>UK</td></tr><tr><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">DMD</td><td colspan="1" rowspan="1">rAAVrh74.MCK.GALGT2</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2; 6.9 and 8.9 years</td><td colspan="1" rowspan="1">isolated limb infusion: injection into the femoral artery of both legs</td><td colspan="1" rowspan="1">1&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">prednisone, 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03333590" id="intref0280">NCT03333590</ext-link> (1/2)</td><td colspan="1" rowspan="1">Flanigan et&#160;al., 2022<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">LHON</td><td colspan="1" rowspan="1">scAAV2-P1ND4v2</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 28; 16&#8211;56 years</td><td colspan="1" rowspan="1">intravitreal</td><td colspan="1" rowspan="1">1&#160;&#215;&#160;10<sup>10</sup> vg/eye</td><td colspan="1" rowspan="1">scAAV2</td><td colspan="1" rowspan="1">prednisolone</td><td colspan="1" rowspan="1">reactive</td><td colspan="1" rowspan="1">management of uveitis</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02161380" id="intref0285">NCT02161380</ext-link> (1)</td><td colspan="1" rowspan="1">Lam et&#160;al., 2022<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">limb-girdle muscular dystrophy</td><td colspan="1" rowspan="1">scAAVrh74.tMCK.hSGCA</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6; 8&#8211;13 years</td><td colspan="1" rowspan="1">intravascular</td><td colspan="1" rowspan="1">3&#160;&#215;&#160;10<sup>12</sup> vg/kg</td><td colspan="1" rowspan="1">AAVrh74</td><td colspan="1" rowspan="1">prednisone, 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A (1/2)</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2019<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">MPS type IIIA</td><td colspan="1" rowspan="1">AAVrh.10-MPS3A</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 4 (patients 1&#8211;3, aged between 5.5 and 6 years; patient 4 aged 2 years 8&#160;months</td><td colspan="1" rowspan="1">intracerebroventicular</td><td colspan="1" rowspan="1">7.2&#160;&#215;&#160;10<sup>11</sup> vg</td><td colspan="1" rowspan="1">AAVrh.10</td><td colspan="1" rowspan="1">tacrolimus - 0.2&#160;mg/kg/day<break/><break/>mycophenolate mofetil, 1,200&#160;mg/m<sup>2</sup> initially, adapted to obtain AUC<sub>0&#8211;12h</sub>&#160;&gt;&#160;30&#160;mg g/L at 7&#160;days post-treatment<break/><break/>prednisolone - 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT01474343" id="intref0290">NCT01474343</ext-link> (1/2)</td><td colspan="1" rowspan="1">Tardieu et&#160;al., 2014, Tardieu et&#160;al., 2017<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref><sup>;</sup><xref rid="bib58" ref-type="bibr"><sup>58</sup></xref></td><td colspan="1" rowspan="1">France</td></tr><tr><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">MPS type IIIB</td><td colspan="1" rowspan="1">rAAV2/5-hNaGlu</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 4; 20, 26, 30, and 53&#160;months</td><td colspan="1" rowspan="1">intracerebroventicular</td><td colspan="1" rowspan="1">4&#160;&#215;&#160;10<sup>12</sup> vg</td><td colspan="1" rowspan="1">AAV2/5</td><td colspan="1" rowspan="1">tacrolimus - 0.2&#160;mg/kg/day<break/>mycophenolate mofetil, 1,200&#160;mg/m<sup>2</sup>/day<break/>prednisolone - 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">EudraCT, number 2012-000856-33, and the International Standard Clinical Trial Registry, number ISRCTN19853672 (1/2)</td><td colspan="1" rowspan="1">Tardieu et&#160;al., 2017<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref></td><td colspan="1" rowspan="1">France</td></tr><tr><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">MPS type IIIB</td><td colspan="1" rowspan="1">rAAV2/5-hNAGLU</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 4; 18&#8211;60&#160;months</td><td colspan="1" rowspan="1">intraparenchymal</td><td colspan="1" rowspan="1">4&#160;&#215;&#160;10<sup>12</sup> vg</td><td colspan="1" rowspan="1">AAV2/5</td><td colspan="1" rowspan="1">tacrolimus - 0.2&#160;mg/kg/day<break/>mycophenolate mofetil, 1,200&#160;mg/m<sup>2</sup>/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03300453" id="intref0295">NCT03300453</ext-link> (1/2)</td><td colspan="1" rowspan="1">Gougeon et&#160;al., 2021, Deiva et&#160;al., 2021<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></td><td colspan="1" rowspan="1">France</td></tr><tr><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">RPE65-Deficient LCA and severe early childhood-onset retinal dystrophy</td><td colspan="1" rowspan="1">rAAV2-CB-hRPE65</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 12; 6&#8211;39 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">6&#160;&#215;&#160;10<sup>11</sup> vg</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">Topical corticosteroids</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">postoperative treatment with topical corticosteroids and antibiotics<break/>no enzyme-linked immunospot response to transgene or capsid<break/>no vector DNA in the blood</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00749957" id="intref0300">NCT00749957</ext-link> (1/2)</td><td colspan="1" rowspan="1">Weleber et&#160;al., 2016<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">RPE65-mediated inherited retinal dystrophy (LCA)</td><td colspan="1" rowspan="1">VN (AAV2-hRPE65v2)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 31; 4 to 44 years</td><td colspan="1" rowspan="1">subretinal/intraorbital</td><td colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>11</sup> vg</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">prednisone; 1&#160;mg/kg/day, maximum dose 40&#160;mg/day and tapered until 3&#160;days before injection of the second eye when the steroid regimen was repeated</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00999609" id="intref0305">NCT00999609</ext-link> (3)</td><td colspan="1" rowspan="1">Russell et&#160;al., 2017<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">SMA</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 32;<break/>7&#8211;55&#160;months)</td><td colspan="1" rowspan="1">intrathecal</td><td colspan="1" rowspan="1">2.4&#160;&#215;&#160;10<sup>14</sup> vg</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">prednisolone, 1&#160;mg/kg/day</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03381729" id="intref0310">NCT03381729</ext-link> (1)</td><td colspan="1" rowspan="1">Finkel et&#160;al., 2023<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr><tr><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">Tay-Sachs disease</td><td colspan="1" rowspan="1">AAVrh8-HEXA and AAVrh8-HEXB</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2; 7 and 30&#160;months</td><td colspan="1" rowspan="1">bilateral thalamic injection</td><td colspan="1" rowspan="1">4.2&#160;&#215;&#160;10<sup>13</sup> vg</td><td colspan="1" rowspan="1">AAVrh8</td><td colspan="1" rowspan="1">patients received a regimen that included rituximab (375&#160;mg m<sup>&#8722;2</sup>), intravenous infusion of methylprednisolone (10&#160;mg kg&#8722;<sup>1</sup>) and sirolimus (1&#160;mg m<sup>&#8722;2</sup>). prednisone (2&#160;mg kg<sup>&#8722;1</sup> per day) was administered for 90&#160;days, and sirolimus was maintained at 3&#8211;7&#160;ng mL<sup>&#8722;</sup>1 for 180&#160;days, both followed by a 1-month taper.</td><td colspan="1" rowspan="1">prophylactic</td><td colspan="1" rowspan="1">B cell levels decreased to &lt;1% of total lymphocytes<break/>intravenous immunoglobulin was given as needed to maintain serum levels between 700 and 1,000&#160;mg dL<sup>&#8722;1</sup><break/>a single dose of rituximab resulted in a reduction in B cell counts for &gt;6&#160;months in each patient</td><td colspan="1" rowspan="1">N/A (expanded-access clinical trial)</td><td colspan="1" rowspan="1">Flotte et&#160;al., 2022<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref></td><td colspan="1" rowspan="1">USA</td></tr></tbody></table><table-wrap-foot><fn><p>AUC, area under the curve; FIX, factor IX; GTMP, no SAEs related to gene therapy product; LHON, Leber hereditary optic neuropathy; N/A. not appliable.</p></fn></table-wrap-foot></table-wrap><fig id="fig1" position="float" orientation="portrait"><label>Figure&#160;1</label><caption><p>Number of studies identified during the systematic review</p><p>(A&#8211;E) Year of study, (B)&#160;serotype, (C)&#160;route of administration, (D)&#160;immunosuppressive regimen, and (E)&#160;immunosuppressant used.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2.2"><title>Types of AAV and routes of administration</title><p id="p0065">A total of 15 different AAV serotypes were used, with the most common being AAV9 (18%; <italic toggle="yes">n</italic>&#160;= 7) (<xref rid="fig1" ref-type="fig">Figure&#160;1</xref>B). In 58% of cases, these AAV vectors were administered via intravenous injection or infusion (<italic toggle="yes">n</italic>&#160;= 22) (<xref rid="fig1" ref-type="fig">Figure&#160;1</xref>C). However, the route of administration was somewhat dependent on the disease being treated and, therefore, the target tissue. For example, in clinical trials for ocular conditions, including LCA, Leber hereditary optic neuropathy, macular degeneration, severe early childhood onset retinal dystrophy, X-linked retinitis pigmentosa, and X-linked retinoschisis, the gene therapy vectors were administered directly into the eye via intravitreal or subretinal injection, whereas all studies relating to hemophilia A and B used intravenous delivery as the preferred route of administration. Given that these 38 studies cover more than 15 different diseases and 15 different AAV serotypes, the doses of each clinical vector are varied and depend on the disease and vector type. The highest single dose in each trial is listed in <xref rid="tbl1" ref-type="table">Table&#160;1</xref>.</p></sec><sec id="sec2.3"><title>Prophylactic immunosuppression</title><sec id="sec2.3.1"><title>Clinical studies</title><p id="p0070">When considering the immunosuppressive treatment used in relation to these AAV gene therapies, in 74% of studies, patients received prophylactic immunosuppression (<italic toggle="yes">n</italic>&#160;= 28) either before (up to 2&#160;weeks in advance, though more commonly 24&#8211;72&#160;h beforehand), on the day of, or immediately after AAV gene therapy administration (<xref rid="fig1" ref-type="fig">Figure&#160;1</xref>D). In the remaining 26% of cases (<italic toggle="yes">n</italic>&#160;= 10), immunosuppressive treatments were used in response to a range of AEs and serious AEs (SAEs) associated with the gene therapy product (<xref rid="tbl1" ref-type="table">Table&#160;1</xref>). A total of 8 different immunosuppressants are detailed in the 38 identified studies (<xref rid="fig1" ref-type="fig">Figure&#160;1</xref>D). The most common immunosuppressants administered were corticosteroids, either prednisolone, its prodrug prednisone, or methylprednisolone. Corticosteroids were used either on their own, or in conjunction with other immunosuppressants, in 95% (36/38) of the identified studies. Other immunosuppressants listed in more than one of the identified studies were tacrolimus (5/34 studies) and mycophenolate mofetil (5/34 studies). Cyclosporine was mentioned in a single study only, as was a combination of sirolimus and rituximab (<xref rid="fig1" ref-type="fig">Figure&#160;1</xref>E). Where specified, the dose of prednisolone ranged from 1 to 2&#160;mg/kg, with a total daily dose in the range of 30&#8211;60&#160;mg. In nearly all cases, prednisolone was administered in a tapering dose over a period of days and weeks, with stated durations ranging from 7 to 133&#160;days. Nine studies (26%) had to increase the dose or introduce additional immunosuppressive agents beyond the initial protocol in response to immunogenicity that occurred in individual patients.</p></sec><sec id="sec2.3.2"><title>Real-world evidence</title><p id="p0075"><xref rid="tbl2" ref-type="table">Table&#160;2</xref> depicts a summary of the 35 real-world studies in this review with the most common studies being SMA (<italic toggle="yes">n</italic>&#160;= 31), inherited retinal dystrophy (<italic toggle="yes">n</italic>&#160;= 3), and hemophilia (<italic toggle="yes">n</italic>&#160;= 1). These real-world outcomes support findings from the interventional trial program and demonstrate the effectiveness of OA in a large patient population, which was consistent with initial clinical data and published 5-year follow-up data. Observed AEs were consistent with the established safety profile of OA. Common AEs included pyrexia, vomiting, thrombocytopenia, and elevated liver enzymes. AEs related to OA were frequent and sometimes serious. Although most AEs were satisfactorily managed in clinical trials, one death was reported in an observational study by Mirea et&#160;al. in 2021.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref><table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;2</label><caption><p>Overview of AAV gene therapy in real-world studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">No.</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">AAV gene therapy</th><th colspan="1" rowspan="1">Vector type</th><th colspan="1" rowspan="1">Dose</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">No. of participants at time of treatment</th><th colspan="1" rowspan="1">Age at injection</th><th colspan="1" rowspan="1">No. of patients dosed</th><th colspan="1" rowspan="1">No. of patients receiving immunosuppressants</th><th colspan="1" rowspan="1">AEs associated with AAV gene therapy</th><th colspan="1" rowspan="1">Immunosuppressive protocol</th><th colspan="1" rowspan="1">Clinical evidence of immunosuppression effectiveness</th><th colspan="1" rowspan="1">Clinical evidence of AAV gene therapy effectiveness</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td rowspan="30" colspan="1">SMA</td><td rowspan="30" colspan="1">onasmnogene abeparvovec</td><td rowspan="30" colspan="1">AAV9</td><td rowspan="30" colspan="1">1.1&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td rowspan="30" colspan="1">intravenous</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 99</td><td colspan="1" rowspan="1">median age: 10&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 99</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">asymptomatic thrombocytopenia<break/>elevated troponin I levels<break/>elevated liver enzyme levels<break/>more pronounced transaminitis<break/>was observed in 70 patients</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) for 30&#160;days; prednisolone (2&#160;mg/kg/day) if transaminase levels exceeded 2-fold the ULNs<break/>IV methylprednisolone in 5 patients with worsening acute transmanisits<break/><italic toggle="yes">N</italic>&#160;= 1 received mycophenolate for chronic transaminitis</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">after OA infusion, mean&#160;&#177; SD change in CHOP-INTEND score was 11.0&#160;&#177; 10.3 with increased score in 66/78 patients (84.6%)<break/>patients aged &lt;6&#160;months had a 13.9 points higher gain in CHOP-INTEND score than patients &#8805;2 years, indicative of improved motor function</td><td colspan="1" rowspan="1">Gowda et&#160;al., 2024<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 168</td><td colspan="1" rowspan="1">median age: 3&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 168</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">hepatotoxicity (<italic toggle="yes">n</italic>&#160;= 49/167; 29.3%), transient thrombocytopenia (<italic toggle="yes">n</italic>&#160;= 23/167; 13.8%), cardiac AEs (<italic toggle="yes">n</italic>&#160;= 22/167; 13.2%), and TMA (<italic toggle="yes">n</italic>&#160;= 1; 0.6%)</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">event-free survival dramatically improved in patients; improved CHOP-INTEND scores; achieved motor milestones</td><td colspan="1" rowspan="1">Servais et&#160;al., 2024<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 76</td><td colspan="1" rowspan="1">median age: 16.8&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 76</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 76</td><td colspan="1" rowspan="1">SAEs were in 8 (11%) children, mostly subacute hepatopathy (<italic toggle="yes">n</italic>&#160;= 7 [9%])<break/>pyrexia (<italic toggle="yes">n</italic>&#160;= 47, 62%)<break/>vomiting or loss of appetite (<italic toggle="yes">n</italic>&#160;= 41, 54%)<break/>minor upper airway infection (<italic toggle="yes">n</italic>&#160;= 6, 8%)<break/>petechiae (<italic toggle="yes">n</italic>&#160;= 1, 1%)<break/>liver enzyme elevation (<italic toggle="yes">n</italic>&#160;= 56, 74%)<break/>thrombocytopenia (<italic toggle="yes">n</italic>&#160;= 59, 78%)<break/>cardiac AEs (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) for &#8805;30&#160;days</td><td colspan="1" rowspan="1">liver enzyme levels normalized</td><td colspan="1" rowspan="1">significant improvements in CHOP-INTEND and HMFSE scores in 49 patients<break/>achievement of motor milestones</td><td colspan="1" rowspan="1">Wei&#946; et&#160;al., 2022<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">1.7&#8211;48&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">fever (<italic toggle="yes">n</italic>&#160;= 6, 66.7%)<break/>pyrexia (<italic toggle="yes">n</italic>&#160;= 47, 62%)<break/>Vomiting (<italic toggle="yes">n</italic>&#160;= 6, 66.7%)<break/>diarrhea (<italic toggle="yes">n</italic>&#160;= 3, 33.3%)<break/>thrombocytopenia (<italic toggle="yes">n</italic>&#160;= 5, 55.6%)<break/>hypertransaminasemia (<italic toggle="yes">n</italic>&#160;= 7, 77.8%)<break/>liver echogenicity changes (<italic toggle="yes">n</italic>&#160;= 1, 11.1%)<break/>increased troponin I (<italic toggle="yes">n</italic>&#160;= 9, 100%)</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">liver enzyme levels normalized</td><td colspan="1" rowspan="1">all patients retained autonomous respiratory capacity without the need for tracheostomy or permanent ventilation and were autonomous in feeding<break/>CHOP-INTEND scores increased in patients over time</td><td colspan="1" rowspan="1">Bitetti et&#160;al., 2013<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">13&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">liver enzyme levels normalized</td><td colspan="1" rowspan="1">improved motor and respiratory function, decreased saliva aspirations</td><td colspan="1" rowspan="1">Nanri et&#160;al., 2024<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">4&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">fatal TMA</td><td colspan="1" rowspan="1">oral steroid (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">not reported due to patient fatality</td><td colspan="1" rowspan="1">Guillou et&#160;al., 2022<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 13</td><td colspan="1" rowspan="1">25.4&#8211;48.0 months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 13</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">no SAEs were related to gene therapy</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">no patients have required increased respiratory support, 2 patients can now stand with assistance</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2021<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">4.5 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">fever, nausea, vomiting, elevated liver enzyme levels, hepatotoxicity, rise in NT-proBNP (heart failure), jaundice, TMA</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">the elevated liver and heart enzymes more than halved after 1&#160;week with increased dose of prednisolone<break/>on day 8 after gene therapy, the patient developed TMA and this resolved within 1&#160;week of eculizumab therapy</td><td colspan="1" rowspan="1">Unreported</td><td colspan="1" rowspan="1">Witte et&#160;al., 2022<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">7&#160;weeks</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">thrombocytopenia, feeding intolerance, mild hepatic dysfunction</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">transaminases were not markedly elevated, safe administration in a patient with initial AAV9 antibody titers &gt;1:50</td><td colspan="1" rowspan="1">walks independently, climbs stairs, has no scoliosis and does not need respiratory support</td><td colspan="1" rowspan="1">Eisenk&#246;lbl and P&#252;hringer, 2024<xref rid="bib116" ref-type="bibr"><sup>116</sup></xref></td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1">7&#8211;445&#160;days</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1">cardiac AEs (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">improvement in CHOP-INTEND scores at 6-month review</td><td colspan="1" rowspan="1">Favia et&#160;al., 2024<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46</td><td colspan="1" rowspan="1">7&#8211;49.5&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46</td><td colspan="1" rowspan="1">asymptomatic elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">only <italic toggle="yes">n</italic>&#160;= 5 had raised liver enzymes and these were asymptomatic<break/>commented that earlier treatment (i.e., before significant motor neuron loss) led to a much smaller proportion of patients needing &gt;60&#160;days of steroid treatment</td><td colspan="1" rowspan="1">improvement in motor milestones with no significant functional decline<break/>some patients also had improved oral feeding and reduced need for respiratory support</td><td colspan="1" rowspan="1">Waldrop et&#160;al., 2024<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref></td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1">1&#8211;23&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1">modest elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2 experienced stabilization, <italic toggle="yes">n</italic>&#160;= 17 experienced improvement in motor function</td><td colspan="1" rowspan="1">Waldrop et&#160;al., 2020<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref></td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 11</td><td colspan="1" rowspan="1">3.6&#160;weeks</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 11</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 11</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">reduced sleep disordered breathing</td><td colspan="1" rowspan="1">Chiang et&#160;al., 2023<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref></td></tr><tr><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 33</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 33</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">increase in maximal mouth opening</td><td colspan="1" rowspan="1">Beri et&#160;al., 2023<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref></td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1">4&#8211;43&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1">elevation of liver enzymes and thrombocytopenia; low-grade fever, 1/25 vomiting, 1/25 borderline high blood pressure</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) with increase to 2&#160;mg/kg/day</td><td colspan="1" rowspan="1">reduced liver enzyme levels; improved platelet levels</td><td colspan="1" rowspan="1">improved motor functionals scores; significant improvements in CHOP-INTEND scores</td><td colspan="1" rowspan="1">Chencheri et&#160;al., 2023<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref></td></tr><tr><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 16</td><td colspan="1" rowspan="1">1.5&#8211;3.4 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 16</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">10/16 had significant kyphosis, 9/16 has scoliosis</td><td colspan="1" rowspan="1">Soini et&#160;al., 2023<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref></td></tr><tr><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46 (another 21 patients with &#8805;6&#160;month follow-up after OA infusion.)</td><td colspan="1" rowspan="1">22&#160;days&#8211;58&#160;months (1/67 child age of 72&#160;months)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46 (for 12&#160;months)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 67</td><td colspan="1" rowspan="1">thrombocytopenia, 15 (22.4%) patients had pyrexia, 14 (20.9%) vomiting or loss of appetite, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day); adjusted to 2&#160;mg/kg per day when increased AST and ALT levels (more than twice normal values) were detected</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">overall significant CHOP-INTEND improvement between T0 and T12 (sitting)<break/>36/46 children with 1-year follow-up (78%) did not need for nutritional support at baseline<break/>after 12&#160;months from the OA, they all remained orally fed<break/>the remaining 10 (22%) remained tube feeding<break/>10 patients (22%) did not need non-invasive ventilation at baseline; 9 of them (90%) remained on spontaneous breathing after 12&#160;months, only 1 needed for non-invasive ventilation</td><td colspan="1" rowspan="1">Pane et&#160;al., 2023<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref></td></tr><tr><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1">18 and 21&#160;days</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1">necrotizing enterocolitis, hematochezia, elevated liver enzymes, vomiting, thrombocytosis in one patient, blood in stool</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) with increase to 2&#160;mg/kg/day</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">Gaillard et&#160;al., 2023<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref></td></tr><tr><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1">11&#160;days and 23&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1">fever, respiratory distress, upper respiratory viral illness, thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">no regression in motor abilities, gradual improvement in motor function and no recurrent infections and illnesses following OA<break/>better progress in motor function observed in patients who received OA earlier and who were presymptomatic</td><td colspan="1" rowspan="1">Tokatly Latzer et&#160;al., 2023<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref></td></tr><tr><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1">121 and 42&#160;days</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">patient 1 became bedridden despite receiving OA (extremities movement improved, predominantly in the upper extremities, and the paradoxical respiration and tongue fasciculation disappeared<break/>the CHOP INTEND score decreased to 15 before treatment but improved to 34 after treatment<break/>he did not need respiratory support and could consume food orally at the age of 2 years and 1&#160;month but had achieved no motor development milestones other than rolling over<break/>he is undergoing physical and occupational therapy). Patient 2 achieved normal motor development (head control, rolling over, sitting without support, standing with support, independent walking, beginning to run</td><td colspan="1" rowspan="1">Sawada et&#160;al., 2022<xref rid="bib127" ref-type="bibr"><sup>127</sup></xref></td></tr><tr><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">19&#8211;527&#160;days</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">improvements of motor function. 3/6 SMA type 1 patients required nutritional support, 4/6 developed scoliosis, 1/6 sleep disturbed breathing<break/>SMA type 2 patient and 2 treated at pre-symptomatic stage did not require nutritional or respiratory support and did not develop a scoliosis</td><td colspan="1" rowspan="1">Stettner et&#160;al., 2023<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref></td></tr><tr><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">5&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">fever and loss of appetite, elevated liver enzyme levels, thrombocytopenia, hyper-ferritinemia</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) with increase to 2&#160;mg/kg/day</td><td colspan="1" rowspan="1">reduced liver enzyme levels, normalized platelet count</td><td colspan="1" rowspan="1">improvement in motor function; acquired a stable sitting position, maintained kneeling position with anterior support, stand unaided with upper limbs support, no respiratory problems. Normal neurocognitive and speech profile, fed by mouth and no swallowing problems</td><td colspan="1" rowspan="1">Tosi et&#160;al., 2022<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref></td></tr><tr><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6 (5 type 1 and 1&#160;type 2)</td><td colspan="1" rowspan="1">7&#8211;24 months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1">elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced GGT, ALT and AST levels</td><td colspan="1" rowspan="1">motor function improvements, no requirements for permanent ventilatory support and no case of mortality</td><td colspan="1" rowspan="1">Lee et&#160;al., 2022<xref rid="bib130" ref-type="bibr"><sup>130</sup></xref></td></tr><tr><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1">7.5&#8211;19.2&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1">fever and/or emesis, thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced ALT and AST levels, normal platelet count</td><td colspan="1" rowspan="1">motor function improvements</td><td colspan="1" rowspan="1">Matesanz et&#160;al., 2021<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref></td></tr><tr><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">&#8804;2 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">elevated liver enzyme levels, vomiting, reduced appetite, high prothrombin time, elevated bilirubin</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">significant improvements in CHOP INTEND scores</td><td colspan="1" rowspan="1">Ali et&#160;al., 2021<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref></td></tr><tr><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10</td><td colspan="1" rowspan="1">19&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10</td><td colspan="1" rowspan="1">hyperthermia, vomiting, lethargy and/or loose stool, thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) with increase to 2&#160;mg/kg/day</td><td colspan="1" rowspan="1">reduced liver enzyme levels, reduced platelet count</td><td colspan="1" rowspan="1">relatively safe and effective with improvements of motor skills</td><td colspan="1" rowspan="1">Nevmerzhitskaya et&#160;al., 2021<xref rid="bib133" ref-type="bibr"><sup>133</sup></xref></td></tr><tr><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1">0.65&#8211;24&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1">vomiting, transaminitis and thrombocytopenia</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels, reduced platelet count</td><td colspan="1" rowspan="1">stabilization or improvement in bulbar or respiratory function</td><td colspan="1" rowspan="1">D'Silva et&#160;al., 2022<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref></td></tr><tr><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1">10&#8211;37&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1">temporary increase in body temperature (&gt; 38.5&#176;C), vomiting, elevated liver enzyme levels, asymptomatic thrombocytopenia, 2/8 patients experienced an increase of pre-existing tremor</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) 7/8 patients; methylprednisolone (20&#160;mg/kg) 1/8 patients</td><td colspan="1" rowspan="1">reduced liver enzyme levels, reduced platelet count, thrombocytes normalized</td><td colspan="1" rowspan="1">sitting without support, no respiratory support and tube feeding</td><td colspan="1" rowspan="1">Friese et&#160;al., 2021<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></td></tr><tr><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">Group 1 <italic toggle="yes">n</italic>&#160;= 7; Group 2 <italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1">2&#8211;6&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1">fever, vomiting, lack of appetite, mild thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">OV after nusinersen did not provide supplementary benefits for motor function or respiratory status<break/>early OV treatment results in better outcomes</td><td colspan="1" rowspan="1">Mirea et&#160;al., 2021<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref></td></tr><tr><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">2&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">head control at 4&#160;months of age, independent walking at 18&#160;months, pulling to stand, walk, and sit independently, and is reaching for objects; eating orally, gaining weight, no respiratory concerns, can say up to 10 words</td><td colspan="1" rowspan="1">Nigro et&#160;al., 2023<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref></td></tr><tr><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">SMA</td><td colspan="1" rowspan="1">onasmnogene abeparvovec (with nusinersen and risdiplam)</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">1.1&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">4&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">moderate/severe TMA, hypertransaminasemia</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">liver enzyme levels normalized</td><td colspan="1" rowspan="1">nusinersen: improvement in motor and bulbar function; onasmnogene abeparvovec: Sitting with support at 2 years old and acquired independent sitting at 27&#160;months. Patient began to eat semisolids orally; risdiplam: further improvements in both motor and bulbar functions one year after risdiplam therapy</td><td colspan="1" rowspan="1">Bitetti et&#160;al., 2023<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref></td></tr><tr><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">Inherited Retinal Dystrophy (RPE-65 mediated)</td><td colspan="1" rowspan="1">VN</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>11</sup> vg per eye</td><td colspan="1" rowspan="1">Subretinal</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1">22&#160;months, 2 years, 5 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3 acute subretinal deposits</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">improved visual function with macular and inferior subretinal deposits improved or resolved</td><td colspan="1" rowspan="1">Lopez et&#160;al., 2023<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref></td></tr><tr><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">Inherited Retinal Dystrophy (RPE-65 mediated)</td><td colspan="1" rowspan="1">VN</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">1.&#160;&#215;&#160;10<sup>11</sup> vg per eye</td><td colspan="1" rowspan="1">Subretinal</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1">18&#8211;49 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>-6</td><td colspan="1" rowspan="1">retinal atrophy in 10/12 eyes (8 mild/2 severe)<break/>increased ocular pressure (3 patients: 6 eyes)<break/>increased intraocular inflammation (2 eyes)<break/>cataracts (4 eyes) glaucoma surgery (2 patients: 4 eyes)<break/>higher occurrence of retinal atrophy and increased IOP than previously reported</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">best-corrected visual acuity remained stable (baseline: 1.28 (&#177;0.71) vs. last follow-up: 1.46 (&#177;0.60); <italic toggle="yes">p</italic>&#160;= 0.25). average white full-field stimulus testing showed a trend toward improvement (baseline: &#8722;4.41 (&#177;10.62) dB vs. last follow-up: &#8722;11.98 (&#177;13.83) dB; <italic toggle="yes">p</italic>&#160;= 0.18).</td><td colspan="1" rowspan="1">Kiraly et&#160;al., 2023<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref></td></tr><tr><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">Inherited Retinal Dystrophy (RPE-65 mediated)</td><td colspan="1" rowspan="1">VN</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>11</sup> vg per eye</td><td colspan="1" rowspan="1">Subretinal</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">39 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">foveal ellipsoid zone loss</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">the first eye showed improvement in rod photoreceptor function with increased peripheral and low luminance vision (baseline VA: 0.9 logMAR and 2-years post-operative VA: 0.7 logMAR. 2ND eye developed loss of foveal photoreceptors. FST improvements were maintained in both eyes. macular edema resolved by 6&#160;weeks of VN</td><td colspan="1" rowspan="1">Jalil et&#160;al., 2023<xref rid="bib136" ref-type="bibr"><sup>136</sup></xref></td></tr><tr><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">Etranacogene dezaparvovec</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">2&#160;&#215;&#160;10<sup>13</sup> vg/kg</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1">43, 47 and 50 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1">headache<break/>transient elevation of C-reactive protein</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">stable durable FIX activity remained after 3 years<break/>discontinued FIX prophylaxis in all patients<break/>clinical phenotype from severe/moderately severe to mild/non-hemophilic<break/>100% decrease in bleeds in 2/3 and 92% in patient 3</td><td colspan="1" rowspan="1">Von Drygalski et&#160;al., 2019<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>FIX, factor IX; GGT, gamma-glutamyl transferase; NT-proBNP; ULN, upper limit of normal.</p></fn></table-wrap-foot></table-wrap></p><p id="p0080">Elevations in liver enzymes were successfully treated with prednisolone, which can also increase the response to treatment by suppressing the antigen-specific T&#160;cell response that clear transduced cells and thus result in a loss of transgene expression.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> In the treatment of inherited retinal dystrophy, all patients reported subjective vision improvement after VN gene therapy. The overall safety and effectiveness of VN treatment align with previous VN clinical trials, excluding the higher occurrence of retinal atrophy and increased ocular pressure observed.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref></p></sec></sec><sec id="sec2.4"><title>Treatment-associated AEs</title><p id="p0085">AEs were observed in 30 of 38 clinical trials involving 19 AAV gene therapies (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>). Increased levels of liver enzymes or liver toxicity were the most frequently reported AE, which was recorded in 21 clinical trials (70%). For the purpose of this review, elevated liver enzymes or liver toxicity included any reference to elevated gamma-glutamyl transferase (GGT), ALT, AST, liver enzymes, liver toxicity, or hepatoxicity. Other frequent AEs included vomiting and nausea (<italic toggle="yes">n</italic>&#160;= 11 [37%]), pyrexia (<italic toggle="yes">n</italic>&#160;= 10 [33%]), and fatigue (<italic toggle="yes">n</italic>&#160;= 6 [20%]). Although AEs were recorded in 30 of the 38 clinical trials, SAEs were only observed in 15 of the included studies (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>), with the highest frequency of SAEs observed in clinical trials for SMA (<italic toggle="yes">n</italic>&#160;= 4), hemophilia A (<italic toggle="yes">n</italic>&#160;= 3), hemophilia B (<italic toggle="yes">n</italic>&#160;= 3), and DMD (<italic toggle="yes">n</italic>&#160;= 2). Four deaths were reported in patients in both low- and high-dose groups because an SAE associated with the treatment protocol in a trial for X-linked myotubular myopathy with resamirigene bilparvovec, an AAV8 clinical vector (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03199469">NCT03199469</ext-link>).<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> Of note, these patients had presented with cholestasis before vector dosing. Due to the clinical vector serotypes used for these diseases, the most common serotypes resulting in SAEs were AAV9 (<italic toggle="yes">n</italic>&#160;= 4, for SMA), AAV5 (<italic toggle="yes">n</italic>&#160;= 2 for hemophilia A and <italic toggle="yes">n</italic>&#160;= 1 for hemophilia B), and rhAAV74 (<italic toggle="yes">n</italic>&#160;= 2, for DMD) after systemic delivery. As detailed in <xref rid="tbl1" ref-type="table">Table&#160;1</xref>, SAEs were associated with the systemic delivery of AAVs with the exception of X-linked retinitis pigmentosa. Elevations in liver enzyme levels were reported as SAEs after clinical vector administration in clinical trials for DMD (<italic toggle="yes">n</italic>&#160;= 2), hemophilia A (<italic toggle="yes">n</italic>&#160;= 2), hemophilia B (<italic toggle="yes">n</italic>&#160;= 3), mucopolysaccharidosis (MPS) type IIIB (<italic toggle="yes">n</italic>&#160;= 1), and SMA (<italic toggle="yes">n</italic>&#160;= 4). Although most studies described management of elevated liver enzyme SAEs via treatment with corticosteroids (even when corticosteroids were administered prophylactically to patients), two studies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03769116" id="intref0015">NCT03769116</ext-link>
<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> and EudraCT 2012-000856-33<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> did not describe any treatment for AEs observed in patients and one reported that there was no clear association between the resolution of elevated ALT levels and prednisolone use.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> The immunosuppressive regimen performed in the trials was prophylactic and AEs recorded in patients were resolved without intervention. All other SAEs relating to clinical vector administration in the studies are detailed in <xref rid="tbl3" ref-type="table">Table&#160;3</xref>. In contrast with clinical trials for the treatment of DMD, hemophilia A and B, MPS type IIIB, and SMA, a clinical trial investigating X-linked retinitis pigmentosa (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03116113">NCT03116113</ext-link>) did not observe any type of SAEs associated with liver enzyme levels after subretinal injection of cotoretigene toliparvovec (BIIB112/AAV8-RPGR).<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> Instead, the SAEs recorded in the study were decreased visual acuity, noninfective retinitis, retinal detachment, and visual impairment. These inflammatory events were further managed with oral prednisolone.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table&#160;3</label><caption><p>Treatment-associated AE overview</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">No.</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">AAV gene therapy</th><th colspan="1" rowspan="1">Serotype</th><th colspan="1" rowspan="1">No. of patients dosed</th><th colspan="1" rowspan="1">Treatment-related SAEs</th><th colspan="1" rowspan="1">Treatment-related AEs</th><th colspan="1" rowspan="1">Frequency of treatment-related AEs</th><th colspan="1" rowspan="1">Management of AEs</th><th colspan="1" rowspan="1">NCT (phase)</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td rowspan="4" colspan="1">DMD</td><td colspan="1" rowspan="1">Delandistrogene moxeparvovec</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">bruising<break/>decreased lymphocyte count<break/>bleeding at femoral catheterization site<break/>vomiting<break/>NB: authors only described events as treatment-emergent and were not specified as treatment-related</td><td colspan="1" rowspan="1">100% (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">no treatment needed for AEs. prednisone administration to patients was prophylactic.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03333590" id="intref0315">NCT03333590</ext-link> (1/2)</td><td colspan="1" rowspan="1">Flanigan et&#160;al., 2022<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Delandistrogene moxeparvovec</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">vomiting (<italic toggle="yes">n</italic>&#160;= 9)<break/>nausea (<italic toggle="yes">n</italic>&#160;= 1)<break/>fatigue (<italic toggle="yes">n</italic>&#160;= 1)<break/>asthenia (<italic toggle="yes">n</italic>&#160;= 1)<break/>decreased appetite (<italic toggle="yes">n</italic>&#160;=&#160;2)<break/>elevated liver enzyme levels (<italic toggle="yes">n</italic>&#160;= 4)</td><td colspan="1" rowspan="1">100% (<italic toggle="yes">n</italic>&#160;= 4)</td><td colspan="1" rowspan="1">elevated &#947;-glutamyl transferase resolved with corticosteroids</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03375164" id="intref0320">NCT03375164</ext-link> (1 and 2)</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2020<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Delandistrogene moxeparvovec</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">rhabdomyolysis<break/>elevated liver enzyme levels<break/>liver injury</td><td colspan="1" rowspan="1">vomiting<break/>decreased appetite<break/>nausea<break/>elevated liver enzyme levels<break/>abdominal pain<break/>increased blood bilirubin<break/>pain in extremity<break/>rhabdomyolysis<break/>pyrexia</td><td colspan="1" rowspan="1">AE: 100% (<italic toggle="yes">n</italic>&#160;= 21)<break/>SAE: 5% (<italic toggle="yes">n</italic>&#160;= 1)</td><td colspan="1" rowspan="1">no treatment described for AEs<break/>prednisone administration to patients was prophylactic.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03769116" id="intref0325">NCT03769116</ext-link> (2)</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2023<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Delandistrogene moxeparvovec</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">elevated liver enzyme levels<break/>vomiting</td><td colspan="1" rowspan="1">vomiting<break/>decreased appetite<break/>increased glutamate dehydrogenase<break/>nausea<break/>constipation<break/>fatigue<break/>elevated liver enzyme levels<break/>increased blood creatine phosphokinase<break/>thrombocytopenia<break/>abdominal pain upper<break/>increased blood lactate dehydrogenase<break/>headache<break/>hemoglobinuria<break/>pyrexia<break/>diarrhea</td><td colspan="1" rowspan="1">AE: 90% (<italic toggle="yes">n</italic>&#160;= 18)<break/>SAE: 10% (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">patients received prophylactic prednisone or prednisolone (1&#160;mg/kg) in addition to baseline corticosteroid dose, for a total &#8804;60&#160;mg/day, which was continued for &#8805;60&#160;days post-treatment and subsequently tapered, depending on serum &#947;-glutamyl transferase levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04626674" id="intref0330">NCT04626674</ext-link> (1b)</td><td colspan="1" rowspan="1">Zaidman et&#160;al., 2023<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td rowspan="3" colspan="1">hemophilia A</td><td colspan="1" rowspan="1">Valoctocogene roxaparvovec</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">134</td><td colspan="1" rowspan="1">elevated liver enzyme levels<break/>headache<break/>arthralgia<break/>nausea</td><td colspan="1" rowspan="1">elevated liver enzyme levels<break/>headache<break/>arthralgia<break/>nausea</td><td colspan="1" rowspan="1">AE: 92% (<italic toggle="yes">n</italic>&#160;= 123)<break/>SAE: 4% (<italic toggle="yes">n</italic>&#160;= 5)</td><td colspan="1" rowspan="1">immunosuppressants were given in relation to an alanine transferase rise<break/>median duration of elevation in ALT was 21&#160;days<break/>there was no apparent relationship between the development of anti-AAV5 antibodies and factor VIII activity</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03370913" id="intref0335">NCT03370913</ext-link> (3)</td><td colspan="1" rowspan="1">Zaidman et&#160;al., 2023<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">Valoctocogene roxaparvovec</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">elevated liver enzyme levels</td><td colspan="1" rowspan="1">elevated liver enzyme levels</td><td colspan="1" rowspan="1">AE by year:<break/>Y1: 86% (<italic toggle="yes">n</italic>&#160;= 6)<break/>Y2: 14% (<italic toggle="yes">n</italic>&#160;= 1)<break/>Y3: 14% (<italic toggle="yes">n</italic>&#160;= 1)<break/>Y4: 29% (<italic toggle="yes">n</italic>&#160;= 2)<break/><break/>SAE by year:<break/>Y1: 17% (<italic toggle="yes">n</italic>&#160;= 1)</td><td colspan="1" rowspan="1">corticosteroids were used prophylactically or in response to elevated ALT levels (1.5&#215; above baseline)<break/>there was no clear association between the resolution of the elevated ALT level and prednisolone use</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02576795" id="intref0340">NCT02576795</ext-link> (1/2)</td><td colspan="1" rowspan="1">Rangarajan et&#160;al., 2017, Long et&#160;al., 2021, Fong et&#160;al., 2022, Pasi et&#160;al., 2021<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref><sup>;</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><sup>;</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref><sup>;</sup><xref rid="bib85" ref-type="bibr"><sup>85</sup></xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">Giroctocogene fitelparvovec</td><td colspan="1" rowspan="1">AAV6</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Pyrexia<break/>Hypotension</td><td colspan="1" rowspan="1">elevated liver enzyme levels<break/>tachycardia<break/>fatigue<break/>myalgia</td><td colspan="1" rowspan="1">SAE: 27% (<italic toggle="yes">n</italic>&#160;= 3)<break/>AE:100% (<italic toggle="yes">n</italic>&#160;= 11)</td><td colspan="1" rowspan="1">liver enzyme levels were managed with tapering corticosteroid administration<break/>hypotension and pyrexia resolved with treatment with electrolytes, norepinephrine, ondansetron, glucose, and paracetamol</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03061201" id="intref0345">NCT03061201</ext-link> (1/2)</td><td colspan="1" rowspan="1">Leavitt et&#160;al., 2024<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td rowspan="8" colspan="1">hemophilia B</td><td colspan="1" rowspan="1">BBM-H901</td><td colspan="1" rowspan="1">dsAAV843</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">pyrexia<break/>elevated liver enzyme levels</td><td colspan="1" rowspan="1">pyrexia (10%, <italic toggle="yes">n</italic>&#160;= 1)<break/>aminotransferase elevations (10%, <italic toggle="yes">n</italic>&#160;= 1)</td><td colspan="1" rowspan="1">glucocorticoid administration</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04135300" id="intref0350">NCT04135300</ext-link> (1)</td><td colspan="1" rowspan="1">Xue et&#160;al., 2022<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">Etranacogene dezaparvovec</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">headache<break/>mild elevation in C-reactive protein levels</td><td colspan="1" rowspan="1">33% (<italic toggle="yes">n</italic>&#160;= 1)</td><td colspan="1" rowspan="1">AEs resolved without intervention</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03489291" id="intref0355">NCT03489291</ext-link> (2b)</td><td colspan="1" rowspan="1">Von Drygalski et&#160;al., 2019<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref></td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Etranacogene dezaparvovec</td><td colspan="1" rowspan="1">AAV6</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">Arthralgia<break/>headache<break/>fatigue<break/>elevated liver enzyme levels<break/>blood creatine kinase increase<break/>back pain<break/>influenza-like illness<break/>diarrhea<break/>nausea</td><td colspan="1" rowspan="1">69% (<italic toggle="yes">n</italic>&#160;= 37)</td><td colspan="1" rowspan="1">glucocorticoid administration for liver enzyme elevations</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03569891" id="intref0360">NCT03569891</ext-link> (3)</td><td colspan="1" rowspan="1">Pipe et&#160;al., 2023<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Verbrinacogene setparvovec</td><td colspan="1" rowspan="1">AAV2/S3</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">elevated liver enzyme levels<break/>decreased coagulation FIX<break/>pulmonary sepsis<break/>arteriovenous fistula thrombosis</td><td colspan="1" rowspan="1">elevated liver enzyme levels<break/>fatigue<break/>increased coagulation FIX<break/>muscle spasms/musculoskeletal pain/myalgia<break/>dyspepsia/eructation<break/>AV fistula thrombosis<break/>decreased coagulation FIX<break/>headache<break/>pulmonary sepsis<break/>somnolence</td><td colspan="1" rowspan="1">AEs: 80% (<italic toggle="yes">n</italic>&#160;= 8)<break/>SAE: 70% (<italic toggle="yes">n</italic>&#160;= 7)<break/>NB: AEs were not observed in patients treated with low dose vector (3.84&#160;&#215;&#160;10<sup>11</sup> vg/kg, <italic toggle="yes">n</italic>&#160;= 2).</td><td colspan="1" rowspan="1">increase in liver enzyme levels were managed with intravenous methylprednisolone and tacrolimus</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03369444" id="intref0365">NCT03369444</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03641703" id="intref0370">NCT03641703</ext-link> (1/2)</td><td colspan="1" rowspan="1">Chowdary et&#160;al., 2022<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">AMT-060</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">elevated liver enzyme levels<break/>Pyrexia</td><td colspan="1" rowspan="1">elevated liver enzyme levels<break/>pyrexia<break/>anxiety<break/>drug ineffective<break/>palpitations<break/>headache<break/>prostatitis<break/>rash</td><td colspan="1" rowspan="1">AEs: 60% (<italic toggle="yes">n</italic>&#160;= 6)<break/>SAEs: 30% (<italic toggle="yes">n</italic>&#160;= 3)</td><td colspan="1" rowspan="1">tapering course of prednisolone</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02396342" id="intref0375">NCT02396342</ext-link> (1/2)</td><td colspan="1" rowspan="1">Majowicz et&#160;al., 2019, Miesbach et&#160;al., 2018<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref><sup>;</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref></td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">SPK-9001</td><td colspan="1" rowspan="1">A novel, bioengineered single-stranded adeno-associated viral vector carrying human FIX variant</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">none reported</td><td colspan="1" rowspan="1">elevated liver enzyme levels</td><td colspan="1" rowspan="1">10% (<italic toggle="yes">n</italic>&#160;= 1)</td><td colspan="1" rowspan="1">2 patients required 60&#160;mg prednisone in the context of ALT rises/immune responses<break/>this was tapered down over 119 and 130&#160;days respectively</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02484092" id="intref0380">NCT02484092</ext-link> (1/2)</td><td colspan="1" rowspan="1">George et&#160;al., 2017<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref></td></tr><tr><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">BAX 335 (scAAV8.FIXR338)</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">fatigue<break/>feeling flushed<break/>headache<break/>infleunza-like symptoms<break/>ankle swelling<break/>elevated liver enzyme levels<break/>high blood pressure<break/>abscess</td><td colspan="1" rowspan="1">57% (<italic toggle="yes">n</italic>&#160;= 4)</td><td colspan="1" rowspan="1">prednisone administration upon detection of high liver enzyme levels</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT01687608" id="intref0385">NCT01687608</ext-link> (1/2)</td><td colspan="1" rowspan="1">Konkle et&#160;al., 2021<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref></td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">scAAV2/8-LP1-hFIXco</td><td colspan="1" rowspan="1">rAAVrh74</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">elevated liver enzyme levels</td><td colspan="1" rowspan="1">lethargy<break/>elevated liver enzyme levels<break/>anemia</td><td colspan="1" rowspan="1">100% (<italic toggle="yes">n</italic>&#160;= 10)</td><td colspan="1" rowspan="1">prednisone, 60&#160;mg/patient with subsequent tapering of the dose<break/>patient 5: 9&#160;weeks<break/>patient 6: 4&#160;weeks</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00979238" id="intref0390">NCT00979238</ext-link> (1/2)</td><td colspan="1" rowspan="1">Nathwani et&#160;al., 2011, Nathwani et&#160;al., 2014<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>;</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref></td></tr><tr><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">LHON</td><td colspan="1" rowspan="1">scAAV2-P1ND4v2</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">none reported</td><td colspan="1" rowspan="1">Uveitis</td><td colspan="1" rowspan="1">29% (<italic toggle="yes">n</italic>&#160;= 8)</td><td colspan="1" rowspan="1">Topical prednisolone</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02161380" id="intref0395">NCT02161380</ext-link> (1)</td><td colspan="1" rowspan="1">Lam et&#160;al., 2022<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref></td></tr><tr><td colspan="1" rowspan="1">17</td><td rowspan="2" colspan="1">MPS type IIIB</td><td colspan="1" rowspan="1">rAAV2/5-hNaGlu</td><td colspan="1" rowspan="1">AAV2/5</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">respiratory tract infection<break/>elevated liver enzyme levels<break/>diarrhea</td><td colspan="1" rowspan="1">upper respiratory tract infection<break/>minor anesthesia-related<break/>diarrhea or gastroenteritis<break/>elevated liver enzyme levels<break/>behavior<break/>anemia<break/>transient hydroelectric disorder<break/>tonsillectomy<break/>adenoidectomy<break/>minimum mitral insufficiency<break/>transient loss of appetite<break/>NB: authors only described events as treatment-emergent and were not specified as treatment-related</td><td colspan="1" rowspan="1">100% (<italic toggle="yes">n</italic>&#160;= 4)</td><td colspan="1" rowspan="1">no treatment described for AEs. prednisone administration to patients was prophylactic.</td><td colspan="1" rowspan="1">EudraCT, number 2012-000856-33, and the International Standard Clinical Trial Registry, number ISRCTN19853672 (1/2)</td><td colspan="1" rowspan="1">Tardieuc et&#160;al., 2017<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref></td></tr><tr><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">rAAV2/5-hNaGlu</td><td colspan="1" rowspan="1">AAV2/5</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">none reported</td><td colspan="1" rowspan="1">upper respiratory tract infection<break/>diarrhea or gastroenteritis<break/>elevated liver enzyme levels<break/>anemia<break/>behavior<break/>bronchitis<break/>cough<break/>pyrexia<break/>conjunctivitis<break/>sleeping disorders<break/>Atopic dermatitis<break/>NB: Authors only described events as treatment-emergent and were not specified as treatment-related</td><td colspan="1" rowspan="1">100% (<italic toggle="yes">n</italic>&#160;= 4)</td><td colspan="1" rowspan="1">no treatment described for AEs<break/>prednisone administration to patients was prophylactic.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03300453">NCT03300453</ext-link> (1/2)</td><td colspan="1" rowspan="1">Gougeon et&#160;al., 2021, Deiva et&#160;al., 2021<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>;</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></td></tr><tr><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">RPE65-Deficient LCA and Severe Early-Childhood Onset Retinal Dystrophy</td><td colspan="1" rowspan="1">rAAV2-CB-hRPE65</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">none reported</td><td colspan="1" rowspan="1">ocular hyperemia<break/>photopsia</td><td colspan="1" rowspan="1">25% (<italic toggle="yes">n</italic>&#160;= 3)</td><td colspan="1" rowspan="1">no treatment described for AEs<break/>topical corticosteroid administration to patients was prophylactic</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00749957" id="intref0400">NCT00749957</ext-link> (1/2)</td><td colspan="1" rowspan="1">Weleber et&#160;al., 2016<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref></td></tr><tr><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">RPE65-mediated inherited retinal dystrophy (LCA)</td><td colspan="1" rowspan="1">AAV8-coRPGR codon optimized RPGR</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">none reported</td><td colspan="1" rowspan="1">anterior uveitis<break/>subretinal inflammation<break/>NB: this was only observed in patients in medium and high dose groups</td><td colspan="1" rowspan="1">33% (<italic toggle="yes">n</italic>&#160;= 6)</td><td colspan="1" rowspan="1">no treatment described for AEs<break/>prednisolone administration to patients was prophylactic</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03116113" id="intref0405">NCT03116113</ext-link> (1/2)</td><td colspan="1" rowspan="1">Cehajic-Kapetanovic et&#160;al., 2020<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref></td></tr><tr><td colspan="1" rowspan="1">21</td><td rowspan="7" colspan="1">SMA</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">76</td><td colspan="1" rowspan="1">subacute hepatopathy<break/>elevated liver enzyme levels<break/>acute liver dysfunction</td><td colspan="1" rowspan="1">pyrexia<break/>vomiting<break/>thrombocytopenia<break/>rashes</td><td colspan="1" rowspan="1">74% (<italic toggle="yes">n</italic>&#160;= 56)</td><td colspan="1" rowspan="1">escalating prednisolone to 2&#160;mg/kg per day for about 4&#160;weeks from 1&#160;mg/kg</td><td colspan="1" rowspan="1">N/A (observational study)</td><td colspan="1" rowspan="1">Wei&#946; et&#160;al., 2022<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref></td></tr><tr><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">none reported</td><td colspan="1" rowspan="1">liver toxicity<break/>thrombocytopenia<break/>increased troponin</td><td colspan="1" rowspan="1">53% (<italic toggle="yes">n</italic>&#160;= 8)</td><td colspan="1" rowspan="1">prednisolone, varying doses depending on AE and patient</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03505099">NCT03505099</ext-link> (3)</td><td colspan="1" rowspan="1">Strauss et&#160;al., 2022<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></td></tr><tr><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">elevated liver enzyme levels (<italic toggle="yes">n</italic>&#160;= 1)</td><td colspan="1" rowspan="1">hypertension<break/>elevated liver enzyme levels<break/>lymphadenopathy<break/>pyrexia<break/>vomiting<break/>prolonged thromboplastin time<break/>increased blood creatine phosphokinase<break/>cardiac murmur<break/>abnormal hair growth<break/>hepatomegaly<break/>pericardial effusion<break/>sinus tachycardia</td><td colspan="1" rowspan="1">37.5% (<italic toggle="yes">n</italic>&#160;= 12)</td><td colspan="1" rowspan="1">increased prednisolone dose administered to patient with elevated liver enzymes<break/>other AEs were resolved without intervention</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03381729">NCT03381729</ext-link> (1)</td><td colspan="1" rowspan="1">Finkel et&#160;al., 2023<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref></td></tr><tr><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">vomiting<break/>elevated liver enzyme levels</td><td colspan="1" rowspan="1">100% (<italic toggle="yes">n</italic>&#160;= 21)</td><td colspan="1" rowspan="1">antiemetic medication<break/>oral and enteral feeding to maintain hydration<break/>systemic corticosteroid administration</td><td colspan="1" rowspan="1">N/A (cohort study)</td><td colspan="1" rowspan="1">D'Silva et&#160;al., 2022<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref></td></tr><tr><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">elevated liver enzyme levels (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">elevated liver enzyme levels below SAE cutoff point (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">27% (<italic toggle="yes">n</italic>&#160;= 4)</td><td colspan="1" rowspan="1">prednisolone treatment</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02122952">NCT02122952</ext-link> (1)</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2017<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></td></tr><tr><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">elevated liver enzymes<break/>pyrexia<break/>vomiting<break/>reduced appetite<break/>exacerbation of hand tremor<break/>thrombocytopenia Increase in troponin I/T, CRP, and monocyte counts</td><td colspan="1" rowspan="1">100% (<italic toggle="yes">n</italic>&#160;= 8)</td><td colspan="1" rowspan="1">prednisolone dose increased above 1&#160;mg/kg</td><td colspan="1" rowspan="1">N/A (retrospective analysis)</td><td colspan="1" rowspan="1">Friese et&#160;al., 2021<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></td></tr><tr><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">OA</td><td colspan="1" rowspan="1">AAV9</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">pyrexia<break/>elevated liver enzyme levels<break/>gastroenteritis<break/>rhinovirus infection<break/>virus infection<break/>feeding disorder<break/>hypernatremia<break/>thrombocytopenia<break/>abnormal coagulation test</td><td colspan="1" rowspan="1">pyrexia<break/>upper respiratory infection<break/>elevated liver enzyme levels<break/>vomiting<break/>constipation<break/>gastroenteritis<break/>rhinovirus infection<break/>virus infection<break/>respiratory tract infection<break/>cough<break/>diarrhea<break/>pneumonia<break/>gastro-esophageal reflux disease<break/>nasopharyngitis<break/>hypertension</td><td colspan="1" rowspan="1">AE: 73% (<italic toggle="yes">n</italic>&#160;= 24)<break/>SAE: 18% (<italic toggle="yes">n</italic>&#160;= 6)</td><td colspan="1" rowspan="1">following the recommendation to increase prophylactic prednisolone dosing for the first 3&#160;days from 1 to 2&#160;mg/kg per day, p (27%) patients received an initial dose of 2&#160;mg/kg per day<break/>the duration of prednisolone dosing ranged from 54 to 235&#160;days (median 65.0 [IQR 13.0]; mean 80.9 [SD 41.2]) and mean daily dose ranged from 0.5 to 1.6&#160;mg/kg per day<break/>2 patients switched to an equivalent dose of hydrocortisone (using a conversion ratio of 1:4) as an alternative to prednisolone on day 165 and day 132 (extended use after the tapering period was prescribed to treat elevated liver enzymes).</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03306277">NCT03306277</ext-link> (3)</td><td colspan="1" rowspan="1">Day et&#160;al., 2021, Mercuri et&#160;al., 2021<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>;</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></td></tr><tr><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">X-linked myotubular myopathy</td><td colspan="1" rowspan="1">Resamirigene bilparvovec</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">increased total bilirubin values<break/>elevation in liver enzyme levels<break/>NB: these resulted in death in 4 participants</td><td colspan="1" rowspan="1">pyrexia<break/>creatine phosphokinase increase<break/>respiratory tract infection</td><td colspan="1" rowspan="1">AE: 96% (<italic toggle="yes">n</italic>&#160;= 23)<break/>SAE: 46% (<italic toggle="yes">n</italic>&#160;= 11)</td><td colspan="1" rowspan="1">prednisone administration was prophylactic. participants presenting with SAEs resulting in death were provided with high-dose prednisolone and other immune-modulating therapies (e.g., prolonged or increased dose of prednisolone, anakinra, tocilizumab, and ruxolitinib) with no apparent benefit.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03199469" id="intref0410">NCT03199469</ext-link> (2/3)</td><td colspan="1" rowspan="1">Shieh et&#160;al., 2023<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref></td></tr><tr><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">X-linked retinitis pigmentosa</td><td colspan="1" rowspan="1">Cotoretigene toliparvovec</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">ocular inflammation leading to reduced visual acuity</td><td colspan="1" rowspan="1">noninfective retinitis<break/>corneal deposits</td><td colspan="1" rowspan="1">AE: 39% (<italic toggle="yes">n</italic>&#160;= 7)<break/>SAE: 11% (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">ocular inflammation-associated SAE were treated with corticosteroids in one participant</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03116113" id="intref0415">NCT03116113</ext-link> (1)</td><td colspan="1" rowspan="1">von Krusenstiern et&#160;al., 2023<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref></td></tr><tr><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">X-linked retinoschisis</td><td colspan="1" rowspan="1">AAV8-RS1</td><td colspan="1" rowspan="1">AAV8</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">None reported</td><td colspan="1" rowspan="1">ocular inflammation<break/>mild vitritis<break/>anterior chamber inflammation</td><td colspan="1" rowspan="1">55% (<italic toggle="yes">n</italic>&#160;= 6)</td><td colspan="1" rowspan="1">subject 9 was pretreated with prednisone and topical steroid at 2&#160;days before dosing and continued beyond day&#160;14<break/>subjects 10 and 11 were treated with cyclosporine at 175&#160;mg twice daily beginning 3&#160;weeks before dosing, and MMF at 500&#160;mg twice daily at 3&#160;weeks and 1000&#160;mg twice daily at 2&#160;weeks before dosing plus prednisone at 60&#160;mg 2&#160;days before vector dosing</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02317887" id="intref0420">NCT02317887</ext-link> (1/2)</td><td colspan="1" rowspan="1">Mishra et&#160;al., 2021<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>FIX, factor IX; LHON, Leber hereditary optic neuropathy.</p></fn></table-wrap-foot></table-wrap></p><p id="p0090">The risk of adverse immune responses from gene therapy is generally related to the type of vector that is used as well as, dose, delivery route,<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> and transgene sequence, which has been found to occur in clinical trials for DMD gene therapy.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>We have summarized the immune responses associated with several vectors (AAV1-2, 2/3, 2.5, 2/8, 5, 8, 9, rh8, rh.10, rh.74, 843, and &#947;-RV), routes (intramuscular, subretinal, intravitreal, intracranial, intraparenchymal, intracerebro-ventricular, low respiratory tract, and cell therapy intravenous) and immunosuppression protocols (<xref rid="tbl4" ref-type="table">Table&#160;4</xref>).<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table&#160;4</label><caption><p>Immunosuppression-associated AEs overview</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">No.</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">AAV gene therapy</th><th colspan="1" rowspan="1">Vector type</th><th colspan="1" rowspan="1">Dose</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">No. of participants at time of treatment</th><th colspan="1" rowspan="1">Age at injection</th><th colspan="1" rowspan="1">No of patients dosed</th><th colspan="1" rowspan="1">No. of patients receiving immunosuppressants</th><th colspan="1" rowspan="1">AEs associated with AAV gene therapy</th><th colspan="1" rowspan="1">Immunosuppressive protocol</th><th colspan="1" rowspan="1">Clinical evidence of immunosuppression effectiveness</th><th colspan="1" rowspan="1">Clinical evidence of AAV gene therapy effectiveness</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td rowspan="31" colspan="1">SMA</td><td rowspan="31" colspan="1">onasmnogene abeparvovec</td><td rowspan="31" colspan="1">AAV9</td><td rowspan="31" colspan="1">1.1&#160;&#215;&#160;10<sup>14</sup> vg/kg</td><td rowspan="31" colspan="1">intravenous</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 99</td><td colspan="1" rowspan="1">median age: 10&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 99</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">asymptomatic thrombocytopenia<break/>elevated troponin I levels<break/>elevated liver enzyme levels<break/>more pronounced transaminitis<break/>was observed in 70 patients</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) for 30&#160;days; prednisolone (2&#160;mg/kg/day) if transaminase levels exceeded 2-fold the ULNs; IV methylprednisolone in 5 patients with worsening acute transmanisits<break/><italic toggle="yes">n</italic>&#160;= 1 received mycophenolate for chronic transaminitis</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">after OA infusion, mean&#160;&#177; SD change in CHOP-INTEND score was 11.0&#160;&#177; 10.3 with increased score in 66/78 patients (84.6%); patients aged &lt;6&#160;months had a 13.9 points higher gain in CHOP-INTEND score than patients &#8805;2 years, indicative of improved motor function.</td><td colspan="1" rowspan="1">Gowda et&#160;al., 2024<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 168</td><td colspan="1" rowspan="1">median age: 3&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 168</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">hepatotoxicity (<italic toggle="yes">n</italic>&#160;= 49/167; 29.3%), transient thrombocytopenia (<italic toggle="yes">n</italic>&#160;= 23/167; 13.8%), cardiac AEs (<italic toggle="yes">n</italic>&#160;= 22/167; 13.2%), and TMA (<italic toggle="yes">n</italic>&#160;= 1; 0.6%)</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">event-free survival dramatically improved in patients; improved CHOP-INTEND scores; achieved motor milestones</td><td colspan="1" rowspan="1">Servais et&#160;al., 2024<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 76</td><td colspan="1" rowspan="1">median age: 16.8&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 76</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 76</td><td colspan="1" rowspan="1">SAEs were in 8 (11%) children, mostly subacute hepatopathy (<italic toggle="yes">n</italic>&#160;= 7 [9%]).<break/>pyrexia (<italic toggle="yes">n</italic>&#160;= 47, 62%)<break/>vomiting or loss of appetite (<italic toggle="yes">n</italic>&#160;= 41, 54%)<break/>minor upper airway infection (<italic toggle="yes">n</italic>&#160;= 6, 8%)<break/>petechiae (<italic toggle="yes">n</italic>&#160;= 1, 1%)<break/>liver enzyme elevation (<italic toggle="yes">n</italic>&#160;= 56, 74%)<break/>thrombocytopenia (<italic toggle="yes">n</italic>&#160;= 59, 78%)<break/>cardiac AEs (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) for &#8805;30&#160;days</td><td colspan="1" rowspan="1">liver enzyme levels normalized</td><td colspan="1" rowspan="1">significant improvements in CHOP-INTEND and HMFSE scores in 49 patients<break/>Achievement of motor milestones</td><td colspan="1" rowspan="1">Wei&#946; et&#160;al., 2022<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">1.7&#8211;48&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">fever (<italic toggle="yes">n</italic>&#160;= 6, 66.7%)<break/>pyrexia (<italic toggle="yes">n</italic>&#160;= 47, 62%)<break/>vomiting (<italic toggle="yes">n</italic>&#160;= 6, 66.7%)<break/>diarrhea (<italic toggle="yes">n</italic>&#160;= 3, 33.3%)<break/>thrombocytopenia (<italic toggle="yes">n</italic>&#160;= 5, 55.6%)<break/>hypertransaminasemia (<italic toggle="yes">n</italic>&#160;= 7, 77.8%)<break/>liver echogenicity changes (<italic toggle="yes">n</italic>&#160;= 1, 11.1%)<break/>Increased troponin I (<italic toggle="yes">n</italic>&#160;= 9, 100%)</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">liver enzyme levels normalized</td><td colspan="1" rowspan="1">all patients retained autonomous respiratory capacity without the need for tracheostomy or permanent ventilation and were autonomous in feeding. CHOP-INTEND scores increased in patients over time</td><td colspan="1" rowspan="1">Bitetti et&#160;al., 2013<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">13&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">liver enzyme levels normalized</td><td colspan="1" rowspan="1">improved motor and respiratory function, decreased saliva aspirations</td><td colspan="1" rowspan="1">Nanri et&#160;al., 2024<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#160;= 1</td><td colspan="1" rowspan="1">4&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">fatal TMA</td><td colspan="1" rowspan="1">Oral steroid (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">not reported due to patient fatality</td><td colspan="1" rowspan="1">Guillou et&#160;al., 2022<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 13</td><td colspan="1" rowspan="1">25.4&#8211;48.0&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 13</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">no SAEs were related to gene therapy</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">no patients have required increased respiratory support, 2 patients can now stand with assistance</td><td colspan="1" rowspan="1">Mendell et&#160;al., 2021<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">4.5 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">fever, nausea, vomiting, elevated liver enzyme levels, hepatotoxicity, rise in NT-proBNP (heart failure), jaundice, TMA</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">the elevated liver and heart enzymes more than halved after one week with increased dose of prednisolone<break/>on day 8 after gene therapy the patient developed TMA and this resolved within 1&#160;week of eculizumab therapy</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">Witte et&#160;al., 2022<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">7&#160;weeks</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">thrombocytopenia, feeding intolerance, mild hepatic dysfunction</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">transaminases were not markedly elevated, safe administration in a patient with initial AAV9 antibody titers &gt;1:50</td><td colspan="1" rowspan="1">walks independently, climbs stairs, has no scoliosis and does not need respiratory support</td><td colspan="1" rowspan="1">Eisenk&#246;lbl and P&#252;hringer, 2024<xref rid="bib116" ref-type="bibr"><sup>116</sup></xref></td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#160;= 8</td><td colspan="1" rowspan="1">7-445&#160;days</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1">cardiac AEs (<italic toggle="yes">n</italic>&#160;= 2)</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">improvement in CHOP-INTEND scores at 6&#160;month review</td><td colspan="1" rowspan="1">Favia et&#160;al., 2024<xref rid="bib116" ref-type="bibr"><sup>117</sup></xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46</td><td colspan="1" rowspan="1">7&#8211;49.5&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46</td><td colspan="1" rowspan="1">asymptomatic elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">only <italic toggle="yes">n</italic>&#160;= 5 had raised liver enzymes and these were asymptomatic<break/>commented that earlier treatment (i.e., before significant motor neuron loss) led to a much smaller proportion of patients needing &gt;60&#160;days of steroid treatment</td><td colspan="1" rowspan="1">improvement in motor milestones with no significant functional decline. Some patients also had improved oral feeding and reduced need for respiratory support</td><td colspan="1" rowspan="1">Waldrop et&#160;al., 2024<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref></td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1">1&#8211;23&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1">modest elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2 experienced stabilization, <italic toggle="yes">n</italic>&#160;= 17 experienced improvement in motor function</td><td colspan="1" rowspan="1">Waldrop et&#160;al., 2020<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref></td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 11</td><td colspan="1" rowspan="1">3.6&#160;weeks</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 11</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 11</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">reduced sleep disordered breathing</td><td colspan="1" rowspan="1">Chiang et&#160;al., 2023<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref></td></tr><tr><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 33</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 33</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">increase in maximal mouth opening</td><td colspan="1" rowspan="1">Beri et&#160;al., 2023<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref></td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1">4&#8211;43&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1">elevation of liver enzymes and thrombocytopenia; low-grade fever, 1/25 vomiting, 1/25 borderline high blood pressure</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) with increase to 2&#160;mg/kg/day</td><td colspan="1" rowspan="1">reduced liver enzyme levels; improved platelet levels</td><td colspan="1" rowspan="1">improved motor functionals scores; significant improvements in CHOP-INTEND scores</td><td colspan="1" rowspan="1">Chencheri et&#160;al., 2023<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref></td></tr><tr><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 16</td><td colspan="1" rowspan="1">1.5&#8211;3.4 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 16</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">10/16 had significant kyphosis, 9/16 has scoliosis</td><td colspan="1" rowspan="1">Soini et&#160;al., 2023<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref></td></tr><tr><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46 (another 21 patients with &#8805;6&#160;month follow-up after OA infusion.)</td><td colspan="1" rowspan="1">22&#160;days&#8211;58&#160;months (1/67 child age of 72&#160;months)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 46 (for 12&#160;months)</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 67</td><td colspan="1" rowspan="1">thrombocytopenia,15 (22.4%) patients had pyrexia,14 (20.9%) vomiting or loss of appetite, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day); adjusted to 2&#160;mg/kg per day when increased AST<break/>and ALT levels (more than twice normal values) were detected</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">overall significant CHOP-INTEND improvement between T0 and T12 (sitting). 36/46 children with one-year follow-up (78%) did not need for nutritional support at baseline; after 12&#160;months from the OA, they all remained orally fed. The remaining ten (22%) remained tube feeding<break/>10 patients (22%) did not need non-invasive ventilation at baseline; nine of them (90%) remained on spontaneous breathing after 12&#160;months, only one needed for non-invasive ventilation</td><td colspan="1" rowspan="1">Pane et&#160;al., 2023<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref></td></tr><tr><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1">18 and 21&#160;days</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1">necrotizing enterocolitis, hematochezia, elevated liver enzymes, vomiting, thrombocytosis in one patient, blood in stool</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) with increase to 2&#160;mg/kg/day</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">Gaillard et&#160;al., 2023<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref></td></tr><tr><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1">11&#160;days and 23&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 25</td><td colspan="1" rowspan="1">fever, respiratory distress, upper respiratory viral illness, thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">no regression in motor abilities, gradual improvement in motor function and no recurrent infections and illnesses following OA<break/>better progress in motor function observed in patients who received OA earlier and who were presymptomatic</td><td colspan="1" rowspan="1">Tokatly Latzer et&#160;al., 2023<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref></td></tr><tr><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1">121 and 42&#160;days</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 2</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">unreported</td><td colspan="1" rowspan="1">patient 1 became bedridden despite receiving OA (extremities movement improved, predominantly in the upper extremities, and the paradoxical respiration and tongue fasciculation disappeared<break/>the CHOP INTEND score decreased to 15 before treatment but improved to 34 after treatment<break/>he did not need respiratory support and could consume food orally at the age of 2 years and 1&#160;month but had achieved no motor development milestones other than rolling over<break/>he is undergoing physical and occupational therapy). Patient 2 achieved normal motor development (head control, rolling over, sitting without support, standing with support, independent walking, beginning to run</td><td colspan="1" rowspan="1">Sawada et&#160;al., 2022<xref rid="bib127" ref-type="bibr"><sup>127</sup></xref></td></tr><tr><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">19&#8211;527&#160;days</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">improvements of motor function<break/>3/6 SMA type 1 patients required nutritional support, 4/6 developed scoliosis, 1/6 sleep disturbed breathing. SMA type 2 patient and two treated at pre-symptomatic stage did not require nutritional or respiratory support and did not develop a scoliosis</td><td colspan="1" rowspan="1">Stettner et&#160;al., 2023<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref></td></tr><tr><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">5&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">fever and loss of appetite, elevated liver enzyme levels, thrombocytopenia, hyper-ferritinemia</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) with increase to 2&#160;mg/kg/day</td><td colspan="1" rowspan="1">reduced liver enzyme levels, normalized platelet count</td><td colspan="1" rowspan="1">improvement in motor function; acquired a stable sitting position, maintained kneeling position with anterior support, stand unaided with upper limbs support, no respiratory problems<break/>normal neurocognitive and speech profile, fed by mouth and no swallowing problems</td><td colspan="1" rowspan="1">Tosi et&#160;al., 2022<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref></td></tr><tr><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6 (5 type 1 and 1 type 2)</td><td colspan="1" rowspan="1">7&#8211;24&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1">elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced GGT, ALT and AST levels</td><td colspan="1" rowspan="1">motor function improvements, no requirements for permanent ventilatory support and no case of mortality</td><td colspan="1" rowspan="1">Lee et&#160;al., 2022<xref rid="bib130" ref-type="bibr"><sup>130</sup></xref></td></tr><tr><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1">7.5&#8211;19.2&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1">fever and/or emesis, thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced ALT and AST levels, normal platelet count</td><td colspan="1" rowspan="1">motor function improvements</td><td colspan="1" rowspan="1">Matesanz et&#160;al., 2021<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref></td></tr><tr><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">&#8804;2 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 9</td><td colspan="1" rowspan="1">elevated liver enzyme levels, vomiting, reduced appetite, high prothrombin time, elevated bilirubin</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">significant improvements in CHOP INTEND scores</td><td colspan="1" rowspan="1">Ali et&#160;al., 2021<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref></td></tr><tr><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10</td><td colspan="1" rowspan="1">19&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 10</td><td colspan="1" rowspan="1">hyperthermia, vomiting, lethargy and/or loose stool, thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) with increase to 2&#160;mg/kg/day</td><td colspan="1" rowspan="1">reduced liver enzyme levels, reduced platelet count</td><td colspan="1" rowspan="1">relatively safe and effective with improvements of motor skills</td><td colspan="1" rowspan="1">Nevmerzhitskaya et&#160;al., 2021<xref rid="bib133" ref-type="bibr"><sup>133</sup></xref></td></tr><tr><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1">0.65&#8211;24&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 21</td><td colspan="1" rowspan="1">vomiting, transaminitis and thrombocytopenia</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels, reduced platelet count</td><td colspan="1" rowspan="1">stabilization or improvement in bulbar or respiratory function</td><td colspan="1" rowspan="1">D'Silva et&#160;al., 2022<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref></td></tr><tr><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1">10&#8211;37&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 8</td><td colspan="1" rowspan="1">temporary increase in body temperature (above 38.5&#176;C), vomiting, elevated liver enzyme levels, asymptomatic thrombocytopenia, 2/8 patients experienced an increase of pre-existing tremor</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day) 7/8 patients; methylprednisolone (20&#160;mg/kg) 1/8 patients</td><td colspan="1" rowspan="1">reduced liver enzyme levels, reduced platelet count, thrombocytes normalized</td><td colspan="1" rowspan="1">sitting without support, no respiratory support and tube feeding</td><td colspan="1" rowspan="1">Friese et&#160;al., 2021<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></td></tr><tr><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">Group 1 <italic toggle="yes">n</italic>&#160;= 7; Group 2 <italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1">2&#8211;6&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 7</td><td colspan="1" rowspan="1">fever, vomiting, lack of appetite, mild thrombocytopenia, elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">OV after nusinersen did not provide supplementary benefits for motor function or respiratory status. Early OV treatment results in better outcomes</td><td colspan="1" rowspan="1">Mirea et&#160;al., 2021<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref></td></tr><tr><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">2&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">elevated liver enzyme levels</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">reduced liver enzyme levels</td><td colspan="1" rowspan="1">head control at 4&#160;months of age, independent walking at 18&#160;months, pulling to stand, walk, and sit independently, and is reaching for objects; eating orally, gaining weight, no respiratory concerns, can say up to 10 words</td><td colspan="1" rowspan="1">Nigro et&#160;al., 2023<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref></td></tr><tr><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">4&#160;months</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">moderate/severe TMA, hypertransaminasemia</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">liver enzyme levels normalized</td><td colspan="1" rowspan="1">nusinersen: improvement in motor and bulbar function; onasmnogene abeparvovec: Sitting with support at 2 years old and acquired independent sitting at 27&#160;months<break/>patient began to eat semisolids orally; risdiplam: further improvements in both motor and bulbar functions one year after risdiplam therapy</td><td colspan="1" rowspan="1">Bitetti et&#160;al., 2023<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">No.</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">AAV gene therapy</th><th colspan="1" rowspan="1">Vector type</th><th colspan="1" rowspan="1">Dose</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">No. of participants at time of treatment</th><th colspan="1" rowspan="1">Age at injection</th><th colspan="1" rowspan="1">No of patients dosed</th><th colspan="1" rowspan="1">No. of patients receiving immunosuppressants</th><th colspan="1" rowspan="1">AEs associated with AAV gene therapy</th><th colspan="1" rowspan="1">Immunosuppressive protocol</th><th colspan="1" rowspan="1">Clinical evidence of immunosuppression effectiveness</th><th colspan="1" rowspan="1">Clinical evidence of AAV gene therapy effectiveness</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">inherited retinal dystrophy (RPE-65 mediated)</td><td colspan="1" rowspan="1">VN</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>11</sup> vg per eye</td><td colspan="1" rowspan="1">Subretinal</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1">22&#160;months, 2 years, 5 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3 acute subretinal deposits</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Improved visual function with macular and inferior subretinal deposits improved or resolved</td><td colspan="1" rowspan="1">Lopez et&#160;al., 2023<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">inherited retinal dystrophy (RPE-65 mediated)</td><td colspan="1" rowspan="1">VN</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>11</sup> vg per eye</td><td colspan="1" rowspan="1">Subretinal</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1">18&#8211;49 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 6</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>-6</td><td colspan="1" rowspan="1">retinal atrophy in 10/12 eyes (8 mild/2 severe)<break/>increased ocular pressure (3 patients: 6 eyes)<break/>Increased intraocular inflammation (2 eyes)<break/>cataracts (4 eyes) glaucoma surgery (2 patients: 4 eyes)<break/>higher occurrence of retinal atrophy and increased IOP than previously reported</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">best-corrected visual acuity remained stable (baseline: 1.28 (&#177;0.71) vs. last follow-up: 1.46 (&#177;0.60); <italic toggle="yes">p</italic>&#160;= 0.25). Average white Full-Field Stimulus Testing (FST) showed a trend toward improvement (baseline: &#8722;4.41 (&#177;10.62) dB vs. last follow-up: &#8722;11.98 (&#177;13.83) dB; <italic toggle="yes">p</italic>&#160;= 0.18).</td><td colspan="1" rowspan="1">Kiraly et&#160;al., 2023<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">inherited retinal dystrophy (RPE-65 mediated)</td><td colspan="1" rowspan="1">VN</td><td colspan="1" rowspan="1">AAV2</td><td colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>11</sup> vg per eye</td><td colspan="1" rowspan="1">subretinal</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">39 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 1</td><td colspan="1" rowspan="1">foveal ellipsoid zone loss</td><td colspan="1" rowspan="1">prednisolone (1&#160;mg/kg/day)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">the first eye showed improvement in rod photoreceptor function with increased peripheral and low luminance vision (baseline VA: 0.9 logMAR and 2-years post-operative VA: 0.7 logMAR. 2ND eye developed loss of foveal photoreceptors. FST improvements were maintained in both eyes. Macular oedema resolved by 6&#160;weeks of VN</td><td colspan="1" rowspan="1">Jalil et&#160;al., 2023<xref rid="bib136" ref-type="bibr"><sup>136</sup></xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">hemophilia B</td><td colspan="1" rowspan="1">etranacogene dezaparvovec</td><td colspan="1" rowspan="1">AAV5</td><td colspan="1" rowspan="1">2&#160;&#215;&#160;10<sup>13</sup> vg/kg</td><td colspan="1" rowspan="1">intravenous</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1">43, 47 and 50 years</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#160;= 3</td><td colspan="1" rowspan="1">headache<break/>transient elevation of C-reactive protein</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">stable durable FIX activity remained after 3 years<break/>discontinued FIX prophylaxis in all patients<break/>clinical phenotype from severe/moderately severe to mild/nonhemophilic<break/>100% decrease in bleeds in 2/3 and 92% in patient 3</td><td colspan="1" rowspan="1">Von Drygalski et&#160;al., 2019<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>GGT, gamma-glutamyl transferase, FIX, factor IX; N/A, not applicable; ULN, upper limit of normal.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.5"><title>Immunosuppression-associated AEs</title><p id="p0095">In addition to treatment-related AEs, we also evaluated the frequency of AEs associated with immunosuppressive protocols, including prophylactic and therapeutic immunosuppression, that were used in the clinical trials. Of the 38 clinical trials that were assessed in this review, only 8 studies (21%) reported having any AEs in patients after the administration of immunosuppressive drugs (<xref rid="tbl4" ref-type="table">Table&#160;4</xref>). Three of the clinical trials resulting in immunosuppression-associated AEs were studies for hemophilia B gene therapy (however, a different AAV gene therapy was used in each case) and another two were for DMD, while studies for hemophilia A, MPS type IIIB, and SMA presented with immunosuppression-associated AEs in one clinical trial each. The immunosuppressive protocols administered to patients were in response to the following most common AEs observed: increased liver enzyme levels, headache, nausea, and fever. Although the AEs resolved after immunosuppressive treatment, a variety of AEs were reported after immunosuppression. This was more apparent in a clinical trial using valoctocogene roxaparvovec (AAV5-hFVIII-SQ; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03370913" id="intref0020">NCT03370913</ext-link>), where 71% of patients showed AEs to glucocorticoids or other immunosuppressants,<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> and trials using verbrinacogene setparvovec (AAV2/S3) gene therapy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03369444" id="intref0025">NCT03369444</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03641703" id="intref0030">NCT03641703</ext-link>),<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> where AEs were recorded in all patients after prednisolone or methylprednisolone treatment and accounted for 24% of all AEs observed.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> However, with the exception of clinical&#160;trial <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03300453" id="intref0035">NCT03300453</ext-link>,<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> the remaining clinical trials listed in <xref rid="tbl4" ref-type="table">Table&#160;4</xref> reported that AEs after prednisone treatment were only&#160;documented in up to two patients.<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> The most common AEs observed in patients after immunosuppressive treatment were insomnia&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03370913" id="intref0040">NCT03370913</ext-link>,<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04135300" id="intref0045">NCT04135300</ext-link>,<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03369444" id="intref0050">NCT03369444</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03641703" id="intref0055">NCT03641703</ext-link><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> and acne (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03370913" id="intref0060">NCT03370913</ext-link>,<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04135300" id="intref0065">NCT04135300</ext-link>,<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00979238" id="intref0070">NCT00979238</ext-link><xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref>). Of note, the authors of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03369444" id="intref0075">NCT03369444</ext-link> and&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03641703" id="intref0080">NCT03641703</ext-link> stated that the AEs recorded in the patients were consistent with the known safety profiles of glucocorticoids and tacrolimus.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> In addition, one subject from clinical trials for DMD and SMA, respectively, presented with AEs after prednisone or prednisolone treatment. Clinical trial <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03333590" id="intref0085">NCT03333590</ext-link><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> recorded a patient with a cushingoid face and weight gain, whereas a study by Friese et&#160;al.<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> recorded a patient presenting with temporary arterial hypertension.</p></sec><sec id="sec2.6"><title>AAV gene therapy and associated immunological responses</title><p id="p0100">The use of AAV gene therapy in subjects with pre-existing immunity or memory response to gene therapy-related viruses could affect the efficacy and the safety of the treatment, constituting one of the major obstacles for gene therapy. Innate and adaptive immunity against the vector capsid or transgenic product may contribute, depending on the magnitude, by varying degrees to immune-mediated rejection and immunotoxicity.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref></p><p id="p0105">Independent of the AAV serotypes and administration route used during these clinical trials, a significant increase in NAbs was reported. Moreover, the presence of an immunosuppressant regimen during these clinical trials could not prevent the development of anti-AAV antibodies. An evaluation of the cellular immune response showed a significant increase in interferon (IFN)-&#947; antigen-specific T&#160;cells after treatment, and an elevation of inflammatory cytokines (e.g., IFN-&#947;, TNF-&#945;) in serum was associated with vector reactogenicity.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref><sup>,</sup><xref rid="bib61" ref-type="bibr"><sup>61</sup></xref><sup>,</sup><xref rid="bib62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="bib69" ref-type="bibr"><sup>69</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref><sup>,</sup><xref rid="bib71" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="bib73" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="bib74" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref><sup>,</sup><xref rid="bib76" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="bib77" ref-type="bibr"><sup>77</sup></xref> Interestingly, only two studies have reported Treg induction, although all patients developed high titers of binding IgG and NAbs.<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref></p><p id="p0110">Currently, the European Medicines Agency<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> and FDA<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref> require an evaluation of humoral immunity by determining both the titers and avidities of antibodies against the AAV transgene product during clinical development. For treatments that include redosing, a comprehensive evaluation of the cellular and humoral responses must be performed and documented with concurrent safety and efficacy data (see Immunogenicity).<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref> Ultimately, however, few studies have reported an evaluation of the titers as the reciprocal of the highest sample dilution that resulted in inhibition of 50% against the AAV vectors used or transgene products.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="bib63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="bib69" ref-type="bibr"><sup>69</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref><sup>,</sup><xref rid="bib82" ref-type="bibr"><sup>82</sup></xref><sup>,</sup><xref rid="bib83" ref-type="bibr"><sup>83</sup></xref><sup>,</sup><xref rid="bib84" ref-type="bibr"><sup>84</sup></xref><sup>,</sup><xref rid="bib85" ref-type="bibr"><sup>85</sup></xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref></p><p id="p0115">Efforts to suppress the immune response to AAV or transgene product have not been consistent. The most common immunosuppressants, corticosteroids, are not always successful in inhibiting the immune response to AAV or attenuating liver toxicity, and there is no correlation with vector or dosing route used. However, mycophenolate mofetil in combination with tacrolimus has provided a safety profile after a long-term follow-up in all children treated in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03300453" id="intref0090">NCT03300453</ext-link>.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0120">The results of this review provide valuable insights into the immunosuppressive protocols and immunological responses associated with various gene therapy treatments. The immune response to AAV gene therapy is complex and can be triggered by vector capsids, genomes, and transgene protein products.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Immune responses to&#160;AAV are ubiquitous and have been seen across various disease states, routes of administration, and capsid serotypes.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> The route&#160;of administration directly influences the vector dose and immunosuppressive protocols. For example, subretinal AAV vector administration performed in several clinical studies of gene transfer for RPE65 deficiency<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> was generally associated with little to no detectable immune response to the capsid or the transgene.</p><p id="p0125">AEs were observed in 30 clinical trials, with the most frequent being increased liver enzyme levels, vomiting and nausea, fever, and fatigue. SAEs were observed in eight studies, with SMA and hemophilia B being the main diseases associated with SAEs. Corticosteroids, including prednisolone, were used to manage these events, even in studies where corticosteroids were administered prophylactically. Interestingly, a phase 1/2 clinical trial for hemophilia B gene therapy did not find a clear association between the resolution of elevated liver enzyme levels and prednisolone use.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref></p><p id="p0130">To decrease AAV immunogenicity, one focus is on decreasing different aspects of immune responses against the capsid to improve patient safety profile and safeguard long-term transgene expression.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> The use of less seroprevalent capsids may reduce the recognition of preformed NAbs.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> One particularly promising strategy is capsid engineering, which has the potential to develop next-generation vectors with multiple improvements compared to current vectors. Current AAV vectors still face limitations in delivering efficiently to specific tissues, often requiring high doses. Higher vector doses have been associated with hepatotoxicity, TMA, and other immune-mediated AEs.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> Additionally, enhancing tropism and transduction efficiency alone would allow for lower doses and significantly decrease toxicity from AAV immunity.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref></p><p id="p0135">One important obstacle is neutralizing anti-AAV antibodies that display a major short- and long-term barrier in delivering gene therapy. Humoral responses against AAV capsid proteins are evaluated in patients before AAV treatment in some trials, and patients with detectable pre-existing antibodies to AAV are excluded. Rates of NAb prevalence in the general population are quoted as 30%&#8211;70% in literature against all various serotypes, with the highest prevalence against AAV2, followed by AAV1.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref><sup>,</sup><xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> In addition, patients who develop <italic toggle="yes">de novo</italic> antibodies after systemic AAV gene therapy have no access to eventual redosing attempts in case of loss of therapy efficacy. Even though gene therapies are designed to be administered only once, the immune response is one factor that jeopardizes the long-term efficacy of transgene expression, which highlights the need for potential redosing strategies for patients. For example, in a recently approved therapy for hemophilia A (Roctavian), factor VIII activity levels declined over 3 years from 52.6 to 18.2 IU/dL. Interestingly, 79% of these 134 patients received corticosteroids in response to ALT elevations. Despite the introduction of corticosteroids, an overall decrease in factor VIII levels was present.<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref> Not only do immune responses prevent the repeated administration of AAV, but AAV immunity can lead to severe toxicity and SAEs, potentially resulting in patient death.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref></p><p id="p0140">To enable redosing, pre-clinical work (including plasmapheresis monoclonal antibody directed to plasma cells and imlifidase injection) has been conducted to evaluate how animals with pre-existing AAV antibodies could be successfully and safely transfected with a transgene carried by an AAV vector.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref><sup>,</sup><xref rid="bib89" ref-type="bibr"><sup>89</sup></xref> In the version of a potential treatment with a second dose of gene therapy, protocols have been developed to tamper the immune reaction during the infusion of the first dose, such as co-administration of sirolimus nanoparticles.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="bib74" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref><sup>,</sup><xref rid="bib76" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="bib77" ref-type="bibr"><sup>77</sup></xref><sup>,</sup><xref rid="bib87" ref-type="bibr"><sup>87</sup></xref><sup>,</sup><xref rid="bib88" ref-type="bibr"><sup>88</sup></xref><sup>,</sup><xref rid="bib89" ref-type="bibr"><sup>89</sup></xref><sup>,</sup><xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> Research findings have shown that incorporating sirolimus into synthetic vaccine particles, co-administered with AAV vectors, hinders the induction of cell-mediated and anti-capsid humoral responses. This results in the inhibition of CD8+ T&#160;cell infiltration in the liver, reduction of B and T&#160;cell activation, and suppression of memory T&#160;cell response in both mice and non-human primates.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> To our best knowledge, this has not yet been translated <italic toggle="yes">in&#160;vivo</italic> in humans.</p><p id="p0145">In this review, a variety of immunosuppressive treatments were noted, including different corticosteroids, tacrolimus, mycophenolate mofetil, cyclosporine, sirolimus, and rituximab. Corticosteroids were the most widely used immunosuppressants for AAV gene therapy clinical studies (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>), either alone or in combination with other drugs, for their global inhibitory effects on innate and adaptive immunity. Corticosteroids are used as immunosuppressants for approved gene therapy products<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> (VN<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> and OA<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>), due to their established safety profiles and effects in preventing or alleviating immune responses. However, the drawbacks of corticosteroids are immunosuppression-associated side effects and non-specific immunosuppression, in particular increased susceptibility to infection.<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref><sup>,</sup><xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> Therefore, careful monitoring and appropriate prophylactic measures should be taken to minimize the risk of infections in patients receiving immunosuppressive treatments. The doses of prednisolone seen in this review ranged from 1 to 2&#160;mg/kg with a total daily dose in the range of 30&#8211;60&#160;mg/day. The duration of corticosteroid treatment ranged dramatically between 7 and 133&#160;days, with other immunosuppressants being used for up to 365&#160;days. This highlights the disparity between studies on the longevity of immunosuppression and differing opinions of where the balance of reducing AAV gene therapy immunogenicity versus the side effects of long-term immunosuppression should be struck. Work is ongoing to refine the immunosuppression regimen with the goal of decreasing vector-related immune response in the early period after treatment. For example, Chowdary et&#160;al.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> adopted a prophylactic immunosuppression regimen to improve the predictability of the dose-response and to increase the chances that normal factor IX levels would be reached and maintained in patients with hemophilia B.</p><p id="p0150">In a review from Oh et&#160;al.<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> investigating steroid-associated side effects in patients with primary proteinuric kidney disease, 62% of patients exposed to steroids developed one SAE. The rate of hypertension was 1.4 times higher than before steroid exposure. Interestingly, the risk of metabolic complications (e.g., diabetes mellitus, overweight, obesity) was also significantly higher after steroid therapy exposure. Taken together, a patient&#8217;s adjusted risk of these complications following steroid exposure was 1.5&#8211;1.8 times that of the risk before exposure. Other studies, such as Movahedi et&#160;al., which analyzed UK and US national databases for nearly 22,000 patients with rheumatoid arthritis, showed that the hazard ratio of steroid-associated diabetes was 1.30 and 1.61, respectively.<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> Another small Japanese study showed corticosteroid-induced diabetes developed in 17&#8211;42 patients (40.5%) undergoing steroid therapy for primary renal disease.<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> In our analysis, often the duration and the dosing regimen of steroid exposure was not always mentioned, and the overall sample size of patients undergoing gene therapy is rather small. In the hemophilia study with valoctocogene roxaparvovec, which has the highest number of patients, the authors reported similar AE rates comparable with the aforementioned publications. In summary, steroid use is related to side effects in gene therapy. Due to the given limitations, the full spectrum and rate of AEs in the context of gene therapy cannot be retrieved based on the current available data, but the available data is in keeping with known side effect profiles seen in high-dose steroid use in other conditions.</p><p id="p0155">Although a wide range of immunosuppressive agents were identified in the study, there is insufficient data available to determine if any of these conferred an additional safety benefit. Only one-quarter of studies reported antibody titers against the vector and transgene, and even fewer evaluated other immune cell responses, e.g., Tregs. Different immunosuppressive drugs have varying modes of action, for example, corticosteroids are non-specific,<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> mycophenolate motefil depletes both T and B cell populations,<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref><sup>,</sup><xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> sirolimus inhibits T and B cell activation and induces Tregs through targeting mTOR,<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> whereas rituximab is an anti-CD20 monoclonal antibody that depletes B cells by inducing apoptosis.<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref> Therefore, better characterization of the different immune cell responses in the future would help identify if any of these agents are more efficacious in decreasing gene therapy immunogenicity and would also identify if additional cell populations need targeting. No agent identified in these studies specifically targeted innate immune responses, although this could be an important direction for the future. As well as engineering transgene to lower their immunogenic CpG content,<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> there are now C3 inhibitors, e.g., APL-9, which have been used during AAV delivery with the aim of dampening the complement pathway.<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref> Some studies already used a combination of immunosuppressive agents to broaden the cell populations they covered; however, with this, the increased likelihood of side effects must be considered. Balancing the risk-benefit profile of immunosuppression continues to be a great challenge for the gene therapy field going forward. Recent prospective trials tested the combination of mTOR inhibitor sirolimus in combination with rituximab.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib99" ref-type="bibr"><sup>99</sup></xref> Preclinical hemophilia A mice models showed that under this combined immunosuppressive therapy, there was no increase in inhibitors following rechallenging with factor VIII protein.<xref rid="bib100" ref-type="bibr"><sup>100</sup></xref> The combined therapy with rituximab and sirolimus was also used in Pompe disease and GM2-gangliosidosis to enable re-administration of AAV.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib101" ref-type="bibr"><sup>101</sup></xref> Despite this first promising data, this drug combination must show its benefit in future trials for patients without sacrificing patient safety.</p><p id="p0160">Gene therapy using AAV vectors shows promise for treating rare genetic diseases. However, the high costs and risks associated with developing these therapies must be considered in the real-world deployment of these therapies (<xref rid="fig2" ref-type="fig">Figure&#160;2</xref>). Conducting robust clinical trials in rare diseases can present complexity and challenges but are necessary to assess the risks and benefits. Improving safety, immunosuppressive regimens, patient risk assessment, and comparing gene therapy to other treatments are key factors to consider.<fig id="fig2" position="float" orientation="portrait"><label>Figure&#160;2</label><caption><p>Graphic summary of findings</p><p>AAV-based gene therapy treatment can induce pre-existing immunity, innate immunity, and adaptive immune response against AAV vectors and transgenic products, inhibiting AAV expression. Patients with pre-existing immunity are unable to receive AAV-based gene therapy treatment. Immunosuppression protocols are used to suppress the immune response and elevate treatment-related AEs, such as the normalization of liver enzymes. Immunosuppression, although potentially essential for some patients to ensure therapeutic benefits of AAV-mediate gene transfer, comes at high costs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><sec id="sec3.1"><title>Conclusion</title><p id="p0165">This review provides valuable information on the immunosuppressive protocols used alongside various gene therapy treatments. Understanding and minimizing immunological responses is crucial for optimizing treatment protocols and ensuring the safety and efficacy of gene therapy interventions. Further research and adherence to evaluation recommendations will contribute to the development of more effective and safer gene therapy approaches in the future.</p></sec></sec><sec id="sec4"><title>Methods</title><p id="p0170">An information specialist (E.H.) searched the following bibliographic databases on May 3, 2024, for studies published from database inception to the search date: Ovid Embase, Ovid MEDLINE, and the Cochrane Register of Controlled Trials. We searched using terms related to monogenic disorders, gene therapy, cell therapy with genetically modified cells, immune modulation, and immune suppression, limited to clinical trial records only. The search strategies for Ovid Embase and Ovid MEDLINE used adapted versions of the Cochrane Highly Sensitive Search Strategies for identifying controlled trials. The full strategies are available in the appendix. All references were exported to EndNote X21 (Thomson Reuters, New York, NY, USA), and duplicates were removed manually. Covidence software was used to manage screening and eligibility. A primary search of the indicated electronic databases resulted in a total of 3,271 articles (<xref rid="fig3" ref-type="fig">Figure&#160;3</xref>). After the removal of duplicates, the remaining studies were screened based on their titles and abstracts by two independent researchers. A total of 517 articles remained after this screening stage and were then evaluated based on their full texts, resulting in 38 clinical trial studies in the final meta-analysis. We excluded literature reviews and conference articles.<fig id="fig3" position="float" orientation="portrait"><label>Figure&#160;3</label><caption><p>PRISMA flow of the selection process of clinical trials</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0175">In addition, 445 real-world studies, case reports, or observational studies were found through a systematic search in the same three databases and registry on May 3, 2024, for studies published from database inception to the search date. We searched using terms related to monogenic disorders, gene therapy, cell therapy with genetically modified cells, immune modulation, and immune suppression, limited to observational studies, case reports, and real-world studies. Conference abstracts and posters were included from Ovid Embase. Again, the full strategies are available in the Appendix. All references were exported to EndNote 21 (Thomson Reuters), and duplicates were removed manually. As shown in the PRISMA flow diagram<xref rid="bib138" ref-type="bibr"><sup>138</sup></xref> (<xref rid="fig4" ref-type="fig">Figure&#160;4</xref>), 337 articles were screened after duplications were eliminated. A total of 35 real-world studies were included in the meta-analysis.<fig id="fig4" position="float" orientation="portrait"><label>Figure&#160;4</label><caption><p>PRISMA flow of the selection process of real-world studies</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Wine</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Flotte</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>P.</given-names></name></person-group><article-title>Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus</article-title><source>Lancet</source><volume>351</volume><year>1998</year><fpage>1702</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)77740-0</pub-id><pub-id pub-id-type="pmid">9734891</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Zuckerman</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Shell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sferra</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Chirmule</surname><given-names>N.</given-names></name><name name-style="western"><surname>Magosin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Propert</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Brown-Parr</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>J.V.</given-names></name><etal/></person-group><article-title>A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis</article-title><source>Hum. Gene Ther.</source><volume>10</volume><year>1999</year><fpage>2973</fpage><lpage>2985</lpage><pub-id pub-id-type="other">10.1089/10430349950016384. PMID: 10609658</pub-id><pub-id pub-id-type="pmid">10609658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/10430349950016384</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Flotte</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Cataltepe</surname><given-names>O.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Batista</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>R.</given-names></name><name name-style="western"><surname>McKenna-Yasek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Douthwright</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gernoux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Blackwood</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>C.</given-names></name><etal/></person-group><article-title>AAV gene therapy for Tay-Sachs disease</article-title><source>Nat. Med.</source><volume>28</volume><year>2022</year><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01664-4</pub-id><pub-id pub-id-type="pmid">35145305</pub-id><pub-id pub-id-type="pmcid">PMC10786171</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>E.</given-names></name></person-group><article-title>Gene therapy death prompts review of adenovirus vector</article-title><source>Science</source><volume>286</volume><year>1999</year><fpage>2244</fpage><lpage>2245</lpage><pub-id pub-id-type="doi">10.1126/science.286.5448.2244</pub-id><pub-id pub-id-type="pmid">10636774</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Somanathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Calcedo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.M.</given-names></name></person-group><article-title>Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial</article-title><source>Mol. Ther.</source><volume>28</volume><year>2020</year><fpage>784</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.01.006</pub-id><pub-id pub-id-type="pmid">32035027</pub-id><pub-id pub-id-type="pmcid">PMC7054813</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Gaudet</surname><given-names>D.</given-names></name><name name-style="western"><surname>M&#233;thot</surname><given-names>J.</given-names></name><name name-style="western"><surname>D&#233;ry</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brisson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Essiembre</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>K.</given-names></name><name name-style="western"><surname>de Wal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Twisk</surname><given-names>J.</given-names></name><name name-style="western"><surname>van den Bulk</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial</article-title><source>Gene Ther.</source><volume>20</volume><year>2013</year><fpage>361</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1038/gt.2012.43</pub-id><pub-id pub-id-type="pmid">22717743</pub-id><pub-id pub-id-type="pmcid">PMC4956470</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Maguire</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Simonelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>E.N.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Mingozzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bennicelli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Banfi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Testa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Surace</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Safety and efficacy of gene transfer for Leber's congenital amaurosis</article-title><source>N.&#160;Engl. J. Med.</source><volume>358</volume><year>2008</year><fpage>2240</fpage><lpage>2248</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802315</pub-id><pub-id pub-id-type="pmid">18441370</pub-id><pub-id pub-id-type="pmcid">PMC2829748</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wellman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.-F.</given-names></name><name name-style="western"><surname>Tillman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wittes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pappas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elci</surname><given-names>O.</given-names></name><name name-style="western"><surname>McCague</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Efficacy and safety of Voretigene NEPARVOVEC (AAV2-hrpe65v2) in patients with RPE65 -mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial</article-title><source>The Lancet</source><volume>390</volume><year>2017</year><fpage>849</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(17)31868-8</pub-id><pub-id pub-id-type="pmcid">PMC5726391</pub-id><pub-id pub-id-type="pmid">28712537</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Maguire</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>High</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Auricchio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Testa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mingozzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bennicelli</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial</article-title><source>Lancet</source><volume>374</volume><year>2009</year><fpage>1597</fpage><lpage>1605</lpage><pub-id pub-id-type="pmid">19854499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(09)61836-5</pub-id><pub-id pub-id-type="pmcid">PMC4492302</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Simonelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Testa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Mingozzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bennicelli</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>K.</given-names></name><name name-style="western"><surname>Banfi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Surace</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration</article-title><source>Mol. Ther.</source><volume>18</volume><year>2010</year><fpage>643</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/mt.2009.277</pub-id><pub-id pub-id-type="pmid">19953081</pub-id><pub-id pub-id-type="pmcid">PMC2839440</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Al-Zaidy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Rodino-Klapac</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Prior</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>K.</given-names></name><name name-style="western"><surname>Church</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy</article-title><source>N.&#160;Engl. J. Med.</source><volume>377</volume><year>2017</year><fpage>1713</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1706198</pub-id><pub-id pub-id-type="pmid">29091557</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Chiriboga</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Darras</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Iannaccone</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>L.D.M.</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>P.B.</given-names></name><etal/></person-group><article-title>Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial</article-title><source>Lancet Neurol.</source><volume>20</volume><year>2021</year><fpage>284</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00001-6</pub-id><pub-id pub-id-type="pmid">33743238</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Mercuri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Baranello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Masson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boespflug-Tanguy</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Daron</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deconinck</surname><given-names>N.</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial</article-title><source>Lancet Neurol.</source><volume>20</volume><year>2021</year><fpage>832</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">34536405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00251-9</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Al-Zaidy</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>McColly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Reash</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Church</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Kleyn</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy</article-title><source>JAMA Neurol.</source><volume>78</volume><year>2021</year><fpage>834</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">33999158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.1272</pub-id><pub-id pub-id-type="pmcid">PMC8129901</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Mahlangu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaczmarek</surname><given-names>R.</given-names></name><name name-style="western"><surname>von Drygalski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Ozelo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Kenet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peyvandi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A</article-title><source>N.&#160;Engl. J. Med.</source><volume>388</volume><year>2023</year><fpage>694</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2211075</pub-id><pub-id pub-id-type="pmid">36812433</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Pipe</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Leebeek</surname><given-names>F.W.G.</given-names></name><name name-style="western"><surname>Recht</surname><given-names>M.</given-names></name><name name-style="western"><surname>Key</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Castaman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miesbach</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lattimore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peerlinck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Van der Valk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Coppens</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B</article-title><source>N.&#160;Engl. J. Med.</source><volume>388</volume><year>2023</year><fpage>706</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2211644</pub-id><pub-id pub-id-type="pmid">36812434</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="book" id="sref17"><part-title>Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene&#160;therapy to treat Duchenne muscular dystrophy</part-title><year>2023</year><publisher-name>Sarepta Therapeutics</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene" id="intref0105">https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene</ext-link></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="book" id="sref18"><part-title>FDA approves first gene therapy for treatment of certain patients with&#160;Duchenne muscular dystrophy</part-title><year>2023</year><publisher-name>FDA</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy" id="intref0110">https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy</ext-link></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Au</surname><given-names>H.K.E.</given-names></name><name name-style="western"><surname>Isalan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mielcarek</surname><given-names>M.</given-names></name></person-group><article-title>Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings</article-title><source>Front. Med.</source><volume>8</volume><year>2021</year><fpage>809118</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.809118</pub-id><pub-id pub-id-type="pmcid">PMC8864161</pub-id><pub-id pub-id-type="pmid">35223884</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ahmadbeigi</surname><given-names>N.</given-names></name></person-group><article-title>Gene therapy clinical trials, where do we go? An overview</article-title><source>Biomed. Pharmacother.</source><volume>153</volume><year>2022</year><fpage>113324</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113324</pub-id><pub-id pub-id-type="pmid">35779421</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Horton</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Saade</surname><given-names>D.</given-names></name><name name-style="western"><surname>Markati</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harriss</surname><given-names>E.</given-names></name><name name-style="western"><surname>B&#246;nnemann</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L.</given-names></name></person-group><article-title>A systematic review of adeno-associated virus gene therapies in neurology: The need for consistent safety monitoring of a promising treatment</article-title><source>J.&#160;Neurol. Neurosurg. Psychiatry</source><volume>93</volume><year>2022</year><fpage>1276</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2022-329431</pub-id><pub-id pub-id-type="pmid">36190933</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Servais</surname><given-names>L.</given-names></name><name name-style="western"><surname>Horton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saade</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bonnemann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><collab>261st ENMC&#160;workshop study group</collab></person-group><article-title>261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, the Netherlands</article-title><source>Neuromuscul. Disord.</source><volume>33</volume><year>2023</year><fpage>884</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2023.09.008</pub-id><pub-id pub-id-type="pmid">37919208</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Mercuri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Deconinck</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mazzone</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oskoui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vuillerot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baranello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boespflug-Tanguy</surname><given-names>O.</given-names></name><name name-style="western"><surname>Goemans</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (sunfish part 2): A phase 3, double-blind, randomised, placebo-controlled trial</article-title><source>Lancet Neurol.</source><volume>21</volume><year>2022</year><fpage>42</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(21)00367-7</pub-id><pub-id pub-id-type="pmid">34942136</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Strauss</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial</article-title><source>Nat. Med.</source><volume>28</volume><year>2022</year><fpage>1390</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01867-3</pub-id><pub-id pub-id-type="pmid">35715567</pub-id><pub-id pub-id-type="pmcid">PMC9205287</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Guillou</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Pellegars</surname><given-names>A.</given-names></name><name name-style="western"><surname>Porcheret</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fr&#233;meaux-Bacchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Allain-Launay</surname><given-names>E.</given-names></name><name name-style="western"><surname>Debord</surname><given-names>C.</given-names></name><name name-style="western"><surname>Denis</surname><given-names>M.</given-names></name><name name-style="western"><surname>P&#233;r&#233;on</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Barn&#233;rias</surname><given-names>C.</given-names></name><name name-style="western"><surname>Desguerre</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy</article-title><source>Blood Adv.</source><volume>6</volume><year>2022</year><fpage>4266</fpage><lpage>4270</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2021006419</pub-id><pub-id pub-id-type="pmid">35584395</pub-id><pub-id pub-id-type="pmcid">PMC9327533</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Chand</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Zaidman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Millner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mackie</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>Goedeker</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Dharnidharka</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Dandamudi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reyna</surname><given-names>S.P.</given-names></name></person-group><article-title>Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series</article-title><source>J.&#160;Pediatr.</source><volume>231</volume><year>2021</year><fpage>265</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2020.11.054</pub-id><pub-id pub-id-type="pmid">33259859</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Patriquin</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Nazy</surname><given-names>I.</given-names></name></person-group><article-title>Thrombotic microangiopathies: A general approach to diagnosis and management</article-title><source>Can. Med. Assoc. J.</source><volume>189</volume><year>2017</year><fpage>E153</fpage><lpage>E159</lpage><pub-id pub-id-type="doi">10.1503/cmaj.160142</pub-id><pub-id pub-id-type="pmid">27754896</pub-id><pub-id pub-id-type="pmcid">PMC5266569</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>R.J.</given-names></name></person-group><article-title>Engineering adeno-associated virus vectors for gene therapy</article-title><source>Nat. Rev. Genet.</source><volume>21</volume><year>2020</year><fpage>255</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0205-4</pub-id><pub-id pub-id-type="pmid">32042148</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Boutin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monteilhet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Veron</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leborgne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Benveniste</surname><given-names>O.</given-names></name><name name-style="western"><surname>Montus</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Masurier</surname><given-names>C.</given-names></name></person-group><article-title>Prevalence of serum IGG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors</article-title><source>Hum. Gene Ther.</source><volume>21</volume><year>2010</year><fpage>704</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1089/hum.2009.182</pub-id><pub-id pub-id-type="pmid">20095819</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Ronzitti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>D.-A.</given-names></name><name name-style="western"><surname>Mingozzi</surname><given-names>F.</given-names></name></person-group><article-title>Human immune responses to adeno-associated virus (AAV) vectors</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><fpage>670</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00670</pub-id><pub-id pub-id-type="pmid">32362898</pub-id><pub-id pub-id-type="pmcid">PMC7181373</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tayler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Asamaphan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Herder</surname><given-names>V.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smollett</surname><given-names>K.</given-names></name><name name-style="western"><surname>Manali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Adeno-associated virus 2 infection in children with non-A-E hepatitis</article-title><source>Nature</source><volume>617</volume><year>2023</year><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05948-2</pub-id><pub-id pub-id-type="pmid">36996873</pub-id><pub-id pub-id-type="pmcid">PMC7617659</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Morfopoulou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Buddle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Torres Montaguth</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guerra-Assun&#231;&#227;o</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Moradi Marjaneh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zennezini Chiozzi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Storey</surname><given-names>N.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Genomic investigations of unexplained acute hepatitis in children</article-title><source>Nature</source><volume>617</volume><year>2023</year><fpage>564</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06003-w</pub-id><pub-id pub-id-type="pmid">36996872</pub-id><pub-id pub-id-type="pmcid">PMC10170458</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Servellita</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sotomayor Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamson</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Foresythe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Bazinet</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Bull</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Goodrich</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Adeno-associated virus type 2 in US children with acute severe hepatitis</article-title><source>Nature</source><volume>617</volume><year>2023</year><fpage>574</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05949-1</pub-id><pub-id pub-id-type="pmid">36996871</pub-id><pub-id pub-id-type="pmcid">PMC10170441</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Petropoulos</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Bashirians</surname><given-names>G.</given-names></name><name name-style="western"><surname>Winburn</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mahn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Somanathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>B.J.</given-names></name></person-group><article-title>Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy</article-title><source>Mol. Ther.</source><volume>31</volume><year>2023</year><fpage>616</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2023.01.010</pub-id><pub-id pub-id-type="pmid">36635967</pub-id><pub-id pub-id-type="pmcid">PMC10014285</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Narkbunnam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Asokan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Manco-Johnson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Monahan</surname><given-names>P.E.</given-names></name><collab>Joint Outcome Study Investigators</collab></person-group><article-title>Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia</article-title><source>Gene Ther.</source><volume>19</volume><year>2012</year><fpage>288</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1038/gt.2011.90</pub-id><pub-id pub-id-type="pmid">21697954</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Calcedo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.M.</given-names></name></person-group><article-title>Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses</article-title><source>J.&#160;Infect. Dis.</source><volume>199</volume><year>2009</year><fpage>381</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1086/595830</pub-id><pub-id pub-id-type="pmid">19133809</pub-id><pub-id pub-id-type="pmcid">PMC10826927</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>DiPrimio</surname><given-names>N.</given-names></name><name name-style="western"><surname>Asokan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goudy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>R.J.</given-names></name></person-group><article-title>Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in&#160;vivo</article-title><source>J.&#160;Virol.</source><volume>83</volume><year>2009</year><fpage>6817</fpage><lpage>6824</lpage><pub-id pub-id-type="doi">10.1128/jvi.00278-09</pub-id><pub-id pub-id-type="pmid">19369348</pub-id><pub-id pub-id-type="pmcid">PMC2698563</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Manno</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Arruda</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Glader</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ragni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rasko</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ozelo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Hoots</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blatt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Konkle</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Successful transduction of lid in hemophilia by Aav-Factor IX and limitations imposed by the host immune response</article-title><source>Nat. Med.</source><volume>12</volume><year>2006</year><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/nm1358</pub-id><pub-id pub-id-type="pmid">16474400</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Fitzpatrick</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Leborgne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barbon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Masat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ronzitti</surname><given-names>G.</given-names></name><name name-style="western"><surname>van Wittenberghe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vignaud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Collaud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simon Sola</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction</article-title><source>Mol. Ther. Methods Clin. Dev.</source><volume>9</volume><year>2018</year><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2018.02.003</pub-id><pub-id pub-id-type="pmid">29766022</pub-id><pub-id pub-id-type="pmcid">PMC5948224</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Harbison</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Weichert</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Gurda</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Chiorini</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Agbandje-McKenna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parrish</surname><given-names>C.R.</given-names></name></person-group><article-title>Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5</article-title><source>J.&#160;Gen. Virol.</source><volume>93</volume><year>2012</year><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1099/vir.0.035113-0</pub-id><pub-id pub-id-type="pmid">22071509</pub-id><pub-id pub-id-type="pmcid">PMC3352341</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Wobus</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>H&#252;gle-D&#246;rr</surname><given-names>B.</given-names></name><name name-style="western"><surname>Girod</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hallek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>J.A.</given-names></name></person-group><article-title>Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection</article-title><source>J.&#160;Virol.</source><volume>74</volume><year>2000</year><fpage>9281</fpage><lpage>9293</lpage><pub-id pub-id-type="doi">10.1128/jvi.74.19.9281-9293.2000</pub-id><pub-id pub-id-type="pmid">10982375</pub-id><pub-id pub-id-type="pmcid">PMC102127</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Agbandje-McKenna</surname><given-names>M.</given-names></name></person-group><article-title>Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors</article-title><source>Front. Immunol.</source><volume>5</volume><year>2014</year><fpage>9</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00009</pub-id><pub-id pub-id-type="pmid">24523720</pub-id><pub-id pub-id-type="pmcid">PMC3906578</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Nathwani</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Tuddenham</surname><given-names>E.G.D.</given-names></name><name name-style="western"><surname>Rangarajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosales</surname><given-names>C.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Linch</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Chowdary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Riddell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pie</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Adenovirus-associated virus vector-mediated gene transfer in hemophilia B</article-title><source>N.&#160;Engl. J. Med.</source><volume>365</volume><year>2011</year><fpage>2357</fpage><lpage>2365</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1108046</pub-id><pub-id pub-id-type="pmid">22149959</pub-id><pub-id pub-id-type="pmcid">PMC3265081</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Nathwani</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Reiss</surname><given-names>U.M.</given-names></name><name name-style="western"><surname>Tuddenham</surname><given-names>E.G.D.</given-names></name><name name-style="western"><surname>Rosales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chowdary</surname><given-names>P.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Della Peruta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lheriteau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Long-term safety and efficacy of factor IX gene therapy in hemophilia B</article-title><source>N.&#160;Engl. J. Med.</source><volume>371</volume><year>2014</year><fpage>1994</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1056/nejmoa1407309</pub-id><pub-id pub-id-type="pmid">25409372</pub-id><pub-id pub-id-type="pmcid">PMC4278802</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Tardieu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Z&#233;rah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Husson</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Bournonville</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deiva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Adamsbaum</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hocquemiller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Broissand</surname><given-names>C.</given-names></name><name name-style="western"><surname>Furlan</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Intracerebral administration of adeno-associated viral vector serotype RH.10 carrying human <italic toggle="yes">sgsh</italic> and <italic toggle="yes">sumf1</italic> cdnas in children with mucopolysaccharidosis type IIIA disease: Results of a phase I/II trial</article-title><source>Hum. Gene Ther.</source><volume>25</volume><year>2014</year><fpage>506</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1089/hum.2013.238</pub-id><pub-id pub-id-type="pmid">24524415</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Coutinho</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>K.E.</given-names></name></person-group><article-title>The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights</article-title><source>Mol. Cell. Endocrinol.</source><volume>335</volume><year>2011</year><fpage>2</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2010.04.005</pub-id><pub-id pub-id-type="pmid">20398732</pub-id><pub-id pub-id-type="pmcid">PMC3047790</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Broering</surname><given-names>R.</given-names></name><name name-style="western"><surname>Montag</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sowa</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Kleinehr</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gerken</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schlaak</surname><given-names>J.F.</given-names></name></person-group><article-title>Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state</article-title><source>Int. Immunol.</source><volume>23</volume><year>2011</year><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxr048</pub-id><pub-id pub-id-type="pmid">21750146</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Chowdary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Makris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boyce</surname><given-names>S.</given-names></name><name name-style="western"><surname>Talks</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reiss</surname><given-names>U.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riddell</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Phase 1&#8211;2 trial of AAVS3 gene therapy in patients with hemophilia B</article-title><source>N.&#160;Engl. J. Med.</source><volume>387</volume><year>2022</year><fpage>237</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1056/nejmoa2119913</pub-id><pub-id pub-id-type="pmid">35857660</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Gougeon</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Poirier-Beaudouin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ausseil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Z&#233;rah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Artaud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heard</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Deiva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tardieu</surname><given-names>M.</given-names></name></person-group><article-title>Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome</article-title><source>Front. Immunol.</source><volume>12</volume><year>2021</year><fpage>655478</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.655478</pub-id><pub-id pub-id-type="pmid">34040605</pub-id><pub-id pub-id-type="pmcid">PMC8141743</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Deiva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ausseil</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Bournonville</surname><given-names>S.</given-names></name><name name-style="western"><surname>Z&#233;rah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Husson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gougeon</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Poirier-Beaudouin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zafeiriou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parenti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heard</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tardieu</surname><given-names>M.</given-names></name></person-group><article-title>Intracerebral Gene therapy in four children with sanfilippo B syndrome: 5.5-year follow up results</article-title><source>Hum. Gene Ther.</source><volume>32</volume><year>2021</year><fpage>1251</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1089/hum.2021.135</pub-id><pub-id pub-id-type="pmid">34405688</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Kraaijeveld</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Leur</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dieterich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peeters</surname><given-names>A.M.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Baan</surname><given-names>C.C.</given-names></name></person-group><article-title>Inhibition of T Helper Cell Differentiation by Tacrolimus or Sirolimus Results in Reduced B-Cell Activation: Effects on T Follicular Helper Cells</article-title><source>Transpl. Proc.</source><volume>51</volume><year>2019</year><fpage>3463</fpage><lpage>3473</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2019.08.039</pub-id><pub-id pub-id-type="pmid">31733794</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dimmock</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Walia</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Sadhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tavakkoli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lipshutz</surname><given-names>G.S.</given-names></name></person-group><article-title>Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches</article-title><source>Hum. Gene Ther.</source><volume>33</volume><year>2022</year><fpage>1228</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1089/hum.2022.138</pub-id><pub-id pub-id-type="pmid">35994385</pub-id><pub-id pub-id-type="pmcid">PMC9808800</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Salabarria</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>N.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Raben</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>M.</given-names></name></person-group><article-title>Advancements in AAV-mediated Gene Therapy for Pompe Disease</article-title><source>J.&#160;Neuromuscul. Dis.</source><volume>7</volume><year>2020</year><fpage>15</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.3233/JND-190426</pub-id><pub-id pub-id-type="pmid">31796685</pub-id><pub-id pub-id-type="pmcid">PMC7029369</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Mirea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shelby</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Axente</surname><given-names>M.</given-names></name><name name-style="western"><surname>Badina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Padure</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leanca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dima</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sporea</surname><given-names>C.</given-names></name></person-group><article-title>Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I</article-title><source>J.&#160;Clin. Med.</source><volume>10</volume><year>2021</year><fpage>5540</fpage><pub-id pub-id-type="doi">10.3390/jcm10235540</pub-id><pub-id pub-id-type="pmid">34884240</pub-id><pub-id pub-id-type="pmcid">PMC8658131</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Kiraly</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cottriall</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Jolly</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Cehajic-Kapetanovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Martinez-Fernandez de la Camara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shanks</surname><given-names>M.</given-names></name><name name-style="western"><surname>Downes</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>MacLaren</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>M.D.</given-names></name></person-group><article-title>Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic <italic toggle="yes">RPE65</italic>-Mediated Inherited Retinal Dystrophies in a Cohort of Patients from a Single Center</article-title><source>Biomolecules</source><volume>13</volume><year>2023</year><fpage>1484</fpage><pub-id pub-id-type="doi">10.3390/biom13101484</pub-id><pub-id pub-id-type="pmid">37892166</pub-id><pub-id pub-id-type="pmcid">PMC10605275</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Shieh</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>M&#252;ller-Felber</surname><given-names>W.</given-names></name><name name-style="western"><surname>B&#246;nnemann</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Seferian</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blaschek</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial</article-title><source>Lancet Neurol.</source><volume>22</volume><year>2023</year><fpage>1125</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(23)00313-7</pub-id><pub-id pub-id-type="pmid">37977713</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Sahenk</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Reash</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Sabo</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy</article-title><source>Front. Cell Dev. Biol.</source><volume>11</volume><year>2023</year><fpage>1167762</fpage><pub-id pub-id-type="doi">10.3389/fcell.2023.1167762</pub-id><pub-id pub-id-type="pmid">37497476</pub-id><pub-id pub-id-type="pmcid">PMC10366687</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Tardieu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Z&#233;rah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gougeon</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Ausseil</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Bournonville</surname><given-names>S.</given-names></name><name name-style="western"><surname>Husson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zafeiriou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parenti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bourget</surname><given-names>P.</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial</article-title><source>Lancet Neurol.</source><volume>16</volume><year>2017</year><fpage>712</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30169-2</pub-id><pub-id pub-id-type="pmid">28713035</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Rangarajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lester</surname><given-names>W.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>D.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Laffan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vettermann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Pasi</surname><given-names>K.J.</given-names></name></person-group><article-title>AAV5&#8211;factor VIII gene transfer in severe hemophilia a</article-title><source>N.&#160;Engl. J. Med.</source><volume>377</volume><year>2017</year><fpage>2519</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.1056/nejmoa1708483</pub-id><pub-id pub-id-type="pmid">29224506</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Cehajic-Kapetanovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>K.</given-names></name><name name-style="western"><surname>Martinez-Fernandez de la Camara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nanda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Salvetti</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Aylward</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR</article-title><source>Nat. Med.</source><volume>26</volume><year>2020</year><fpage>354</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0763-1</pub-id><pub-id pub-id-type="pmid">32094925</pub-id><pub-id pub-id-type="pmcid">PMC7104347</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Verdera</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Kuranda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mingozzi</surname><given-names>F.</given-names></name></person-group><article-title>AAV vector immunogenicity in humans: A long journey to successful Gene Transfer</article-title><source>Mol. Ther.</source><volume>28</volume><year>2020</year><fpage>723</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.12.010</pub-id><pub-id pub-id-type="pmid">31972133</pub-id><pub-id pub-id-type="pmcid">PMC7054726</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>B&#246;nnemann</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Belluscio</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>C.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name></person-group><article-title>Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy</article-title><source>N.&#160;Engl. J. Med.</source><volume>388</volume><year>2023</year><fpage>2294</fpage><lpage>2296</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2212912</pub-id><pub-id pub-id-type="pmid">37314712</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor ix administered with prophylactic glucocorticoids in patients with haemophilia B: A single-centre, single-arm, phase 1, pilot trial</article-title><source>Lancet Haematol.</source><volume>9</volume><year>2022</year><fpage>e504</fpage><lpage>e513</lpage><pub-id pub-id-type="doi">10.1016/s2352-3026(22)00113-2</pub-id><pub-id pub-id-type="pmid">35598604</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Flanigan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Vetter</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frair</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chicoine</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheatham</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Cheatham</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>A first-in-human phase I/IIA gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2</article-title><source>Mol. Ther. Methods Clin. Dev.</source><volume>27</volume><year>2022</year><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2022.08.009</pub-id><pub-id pub-id-type="pmid">36186954</pub-id><pub-id pub-id-type="pmcid">PMC9483573</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Friese</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geitmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holzwarth</surname><given-names>D.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sassen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baur</surname><given-names>U.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J.</given-names></name></person-group><article-title>Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience</article-title><source>J.&#160;Neuromuscul. Dis.</source><volume>8</volume><year>2021</year><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.3233/JND-200593</pub-id><pub-id pub-id-type="pmid">33427694</pub-id><pub-id pub-id-type="pmcid">PMC8075402</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sahenk</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nease</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Nicholl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Zaidy</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Assessment of systemic delivery of Raavrh74.mhck7.micro-dystrophin in children with Duchenne muscular dystrophy</article-title><source>JAMA Neurol.</source><volume>77</volume><year>2020</year><fpage>1122</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2020.1484</pub-id><pub-id pub-id-type="pmid">32539076</pub-id><pub-id pub-id-type="pmcid">PMC7296461</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Veron</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kuranda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hardet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hock</surname><given-names>M.B.</given-names></name><etal/></person-group><article-title>Early phase clinical immunogenicity of Valoctocogene Roxaparvovec, an AAV5-mediated gene therapy for hemophilia A</article-title><source>Mol. Ther.</source><volume>29</volume><year>2021</year><fpage>597</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.12.008</pub-id><pub-id pub-id-type="pmid">33309883</pub-id><pub-id pub-id-type="pmcid">PMC7854299</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Majowicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nijmeijer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lampen</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Spronck</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Haan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petry</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Deventer</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tangelder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>V.</given-names></name></person-group><article-title>Therapeutic hfix activity achieved after single AAV5-hfix treatment in hemophilia B patients and nhps with pre-existing Anti-AAV5 Nabs</article-title><source>Mol. Ther. Methods Clin. Dev.</source><volume>14</volume><year>2019</year><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2019.05.009</pub-id><pub-id pub-id-type="pmid">31276009</pub-id><pub-id pub-id-type="pmcid">PMC6586596</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Hauswirth</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Aleman</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cideciyan</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Conlon</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Boye</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Flotte</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>S.G.</given-names></name></person-group><article-title>Treatment of leber congenital amaurosis due to<italic toggle="yes">rpe65</italic>mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial</article-title><source>Hum. Gene Ther.</source><volume>19</volume><year>2008</year><fpage>979</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1089/hum.2008.107</pub-id><pub-id pub-id-type="pmid">18774912</pub-id><pub-id pub-id-type="pmcid">PMC2940541</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Finkel</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Darras</surname><given-names>B.T.</given-names><suffix>JR.</suffix></name><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Day</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Zaidman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>P.B.</given-names></name><etal/></person-group><article-title>Intrathecal Onasemnogene Abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: Phase I ascending-dose study (strong)</article-title><source>J.&#160;Neuromuscul. Dis.</source><volume>10</volume><year>2023</year><fpage>389</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.3233/jnd-221560</pub-id><pub-id pub-id-type="pmid">36911944</pub-id><pub-id pub-id-type="pmcid">PMC10200150</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vijayasarathy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cukras</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Sieving</surname><given-names>P.A.</given-names></name></person-group><article-title>Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIA gene therapy trial</article-title><source>Mol. Ther.</source><volume>29</volume><year>2021</year><fpage>2030</fpage><lpage>2040</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.02.013</pub-id><pub-id pub-id-type="pmid">33601057</pub-id><pub-id pub-id-type="pmcid">PMC8178519</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chulay</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Trapnell</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Humphries</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sandhaus</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>McElvaney</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Messina</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rouhani</surname><given-names>F.N.</given-names></name><etal/></person-group><article-title>Human Treg responses allow sustained recombinant adeno-associated virus&#8211;mediated transgene expression</article-title><source>J.&#160;Clin. Invest.</source><volume>123</volume><year>2013</year><fpage>5310</fpage><lpage>5318</lpage><pub-id pub-id-type="doi">10.1172/jci70314</pub-id><pub-id pub-id-type="pmid">24231351</pub-id><pub-id pub-id-type="pmcid">PMC3859421</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Muhuri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name></person-group><article-title>Overcoming innate immune barriers that impede AAV gene therapy vectors</article-title><source>J.&#160;Clin. Invest.</source><volume>131</volume><year>2021</year><fpage>e143780</fpage><pub-id pub-id-type="doi">10.1172/jci143780</pub-id><pub-id pub-id-type="pmid">33393506</pub-id><pub-id pub-id-type="pmcid">PMC7773343</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>MacLaren</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Groppe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Cottriall</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Tolmachova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>During</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cremers</surname><given-names>F.P.M.</given-names></name><name name-style="western"><surname>Black</surname><given-names>G.C.M.</given-names></name><etal/></person-group><article-title>Retinal gene therapy in patients with CHOROIDEREMIA: Initial findings from a phase 1/2 clinical trial</article-title><source>The Lancet</source><volume>383</volume><year>2014</year><fpage>1129</fpage><lpage>1137</lpage><pub-id pub-id-type="other">10.1016/s0140 6736(13)62117-0</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)62117-0</pub-id><pub-id pub-id-type="pmcid">PMC4171740</pub-id><pub-id pub-id-type="pmid">24439297</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Perocheau</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Antinao Diaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waddington</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Gilmour</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eaglestone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lisowski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thrasher</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>I.E.</given-names></name><etal/></person-group><article-title>Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort</article-title><source>Hum. Gene Ther.</source><volume>30</volume><year>2019</year><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1089/hum.2018.098</pub-id><pub-id pub-id-type="pmid">30027761</pub-id><pub-id pub-id-type="pmcid">PMC6343184</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Calcedo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Sanmiguel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morizono</surname><given-names>H.</given-names></name><name name-style="western"><surname>Batshaw</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.M.</given-names></name></person-group><article-title>The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques</article-title><source>Mol. Ther.</source><volume>18</volume><year>2010</year><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/mt.2009.245</pub-id><pub-id pub-id-type="pmid">19888196</pub-id><pub-id pub-id-type="pmcid">PMC2839221</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="other" id="sref77"><article-title>Annex I summary of Product Characteristics - European Medicines Agency</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/roctavian-epar-product-information_en.pdf" id="intref7544">https://www.ema.europa.eu/en/documents/product-information/roctavian-epar-product-information_en.pdf</ext-link><comment>accessed date August 02, 2024</comment></element-citation></ref><ref id="bib78"><label>78</label><mixed-citation publication-type="other" id="sref78">Guideline on the Quality, Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products. (EMA/CAT/80183/2014). European Medicines Agency. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-aspects-gene-therapy-medicinal-products_en.pdf" id="intref0120">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-aspects-gene-therapy-medicinal-products_en.pdf</ext-link>. accessed date August 02, 2024.</mixed-citation></ref><ref id="bib79"><label>79</label><mixed-citation publication-type="other" id="sref79">Center for Drug Evaluation and Research (no date) Guidance for Industry, U.S. Food and Drug Administration. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug" id="intref0125">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug</ext-link>. accessed date August 02, 2024.</mixed-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sahenk</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rodino-Klapac</surname><given-names>L.R.</given-names></name></person-group><article-title>Duchenne muscular dystrophy exon-skipping trials</article-title><source>Muscle Gene Ther.</source><year>2019</year><fpage>727</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-03095-7_42</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Fong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sihn</surname><given-names>C.-R.</given-names></name><name name-style="western"><surname>Mattis</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rangarajan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Interindividual variability in transgene mrna and protein production following adeno-associated virus gene therapy for hemophilia A</article-title><source>Nat. Med.</source><volume>28</volume><year>2022</year><fpage>789</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01751-0</pub-id><pub-id pub-id-type="pmid">35411075</pub-id><pub-id pub-id-type="pmcid">PMC9018415</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Konkle</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Escobar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Josephson</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Young</surname><given-names>G.</given-names></name><name name-style="western"><surname>von Drygalski</surname><given-names>A.</given-names></name><name name-style="western"><surname>McPhee</surname><given-names>S.W.J.</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Bilic</surname><given-names>I.</given-names></name><name name-style="western"><surname>de la Rosa</surname><given-names>M.</given-names></name><etal/></person-group><article-title>BAX 335 hemophilia B gene therapy clinical trial results: Potential impact of CPG sequences on gene expression</article-title><source>Blood</source><volume>137</volume><year>2021</year><fpage>763</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1182/blood.2019004625</pub-id><pub-id pub-id-type="pmid">33067633</pub-id><pub-id pub-id-type="pmcid">PMC7885820</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Wei&#223;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Johannsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brennenstuhl</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>G.</given-names></name><name name-style="western"><surname>Flotats-Bastardas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stoltenburg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Illsinger</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24&#160;months or younger and bodyweight up to 15&#160;kg: an observational cohort study</article-title><source>Lancet Child Adolesc. Health</source><volume>6</volume><year>2022</year><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S2352-4642(21)00287-X</pub-id><pub-id pub-id-type="pmid">34756190</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Rakoczy</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.-M.</given-names></name><name name-style="western"><surname>Magno</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Wikstrom</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>French</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Blumenkranz</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Chalberg</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Degli-Esposti</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Constable</surname><given-names>I.J.</given-names></name></person-group><article-title>Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 Year follow-up of a phase 1 randomised clinical trial</article-title><source>Lancet</source><volume>386</volume><year>2015</year><fpage>2395</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(15)00345-1</pub-id><pub-id pub-id-type="pmid">26431823</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Pasi</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Laffan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rangarajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lester</surname><given-names>W.</given-names></name><name name-style="western"><surname>Symington</surname><given-names>E.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Persistence of haemostatic response following gene therapy with Valoctocogene Roxaparvovec in severe haemophilia a</article-title><source>Haemophilia</source><volume>27</volume><year>2021</year><fpage>947</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1111/hae.14391</pub-id><pub-id pub-id-type="pmid">34378280</pub-id><pub-id pub-id-type="pmcid">PMC9291073</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Miesbach</surname><given-names>W.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Coppens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kampmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Klamroth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schutgens</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tangelder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Castaman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schw&#228;ble</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bonig</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B</article-title><source>Blood</source><volume>131</volume><year>2018</year><fpage>1022</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-09-804419</pub-id><pub-id pub-id-type="pmid">29246900</pub-id><pub-id pub-id-type="pmcid">PMC5833265</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Chandra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Long</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Fonck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Melton</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Arens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Woloszynek</surname><given-names>J.</given-names></name><name name-style="western"><surname>O'Neill</surname><given-names>C.A.</given-names></name></person-group><article-title>Safety findings of dosing gene therapy vectors in NHP with pre-existing or treatment-emergent anti-capsid antibodies</article-title><source>Toxicol. Pathol.</source><volume>51</volume><year>2023</year><fpage>246</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1177/01926233231202995</pub-id><pub-id pub-id-type="pmid">37921115</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>E.S.B.</given-names></name><name name-style="western"><surname>Goens</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Susta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Banadyga</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wootton</surname><given-names>S.K.</given-names></name></person-group><article-title>Recent advancements in aav-vectored immunoprophylaxis in the nonhuman primate model</article-title><source>Biomedicines</source><volume>11</volume><year>2023</year><fpage>2223</fpage><pub-id pub-id-type="doi">10.3390/biomedicines11082223</pub-id><pub-id pub-id-type="pmid">37626720</pub-id><pub-id pub-id-type="pmcid">PMC10452516</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Meliani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boisgerault</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hardet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marmier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Collaud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ronzitti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Leborgne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Costa Verdera</surname><given-names>H.</given-names></name><name name-style="western"><surname>Simon Sola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration</article-title><source>Nat. Commun.</source><volume>9</volume><year>2018</year><fpage>4098</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06621-3</pub-id><pub-id pub-id-type="pmid">30291246</pub-id><pub-id pub-id-type="pmcid">PMC6173722</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Rhen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cidlowski</surname><given-names>J.A.</given-names></name></person-group><article-title>Anti-inflammatory action of glucocorticoids &#8212; new mechanisms for old drugs</article-title><source>N.&#160;Engl. J. Med.</source><volume>353</volume><year>2005</year><fpage>1711</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1056/nejmra050541</pub-id><pub-id pub-id-type="pmid">16236742</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Youssef</surname><given-names>J.</given-names></name><name name-style="western"><surname>Novosad</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Winthrop</surname><given-names>K.L.</given-names></name></person-group><article-title>Infection risk and safety of corticosteroid use</article-title><source>Rheum. Dis. Clin. North Am.</source><volume>42</volume><year>2016</year><fpage>157</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.rdc.2015.08.004</pub-id><pub-id pub-id-type="pmid">26611557</pub-id><pub-id pub-id-type="pmcid">PMC4751577</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>L.</given-names></name></person-group><article-title>A versatile toolkit for overcoming AAV immunity</article-title><source>Front. Immunol.</source><volume>13</volume><year>2022</year><fpage>991832</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.991832</pub-id><pub-id pub-id-type="pmid">36119036</pub-id><pub-id pub-id-type="pmcid">PMC9479010</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Waldo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paez-Cruz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gipson</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Pesenson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Selewski</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Kamil</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Massengill</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Lafayette</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Modes</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease</article-title><source>Kidney Int. Rep.</source><volume>4</volume><year>2019</year><fpage>1608</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2019.08.019</pub-id><pub-id pub-id-type="pmid">31891002</pub-id><pub-id pub-id-type="pmcid">PMC6933464</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Movahedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beauchamp</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Abrahamowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Michaud</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pedro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>W.G.</given-names></name></person-group><article-title>Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis</article-title><source>Arthritis Rheumatol.</source><volume>68</volume><year>2016</year><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="pmid">26663814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.39537</pub-id><pub-id pub-id-type="pmcid">PMC4982029</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Uzu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kanasaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Isshiki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Araki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sugiomoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Haneda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kashiwagi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>A.</given-names></name></person-group><article-title>Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases</article-title><source>Nephron. Clin. Pract.</source><volume>105</volume><year>2007</year><fpage>c54</fpage><lpage>c57</lpage><pub-id pub-id-type="pmid">17135768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000097598</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Kropf</surname><given-names>E.</given-names></name><name name-style="western"><surname>Deschatelets</surname><given-names>P.</given-names></name><name name-style="western"><surname>Francois</surname><given-names>C.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>W.J.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Singh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Majowicz</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood</article-title><source>Front. Immunol.</source><volume>13</volume><year>2022</year><fpage>999021</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.999021</pub-id><pub-id pub-id-type="pmid">36189251</pub-id><pub-id pub-id-type="pmcid">PMC9523746</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Bertolini</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Shirley</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zolotukhin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kaisho</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.R.P.</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>R.W.</given-names></name></person-group><article-title>Effect of CPG depletion of Vector Genome on CD8+ T&#160;cell responses in Aav Gene therapy</article-title><source>Front. Immunol.</source><volume>12</volume><year>2021</year><fpage>672449</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.672449</pub-id><pub-id pub-id-type="pmid">34135899</pub-id><pub-id pub-id-type="pmcid">PMC8200677</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Doshi</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Raffini</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>George</surname><given-names>L.A.</given-names></name></person-group><article-title>Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors</article-title><source>J.&#160;Thromb. Haemost.</source><volume>18</volume><year>2020</year><fpage>848</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1111/jth.14740</pub-id><pub-id pub-id-type="pmid">31985872</pub-id><pub-id pub-id-type="pmcid">PMC7888210</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Biswas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palaschak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.R.P.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>J.</given-names></name><name name-style="western"><surname>Markusic</surname><given-names>D.M.</given-names></name></person-group><article-title>B cell depletion eliminates FVIII memory B cells and enhances AAV8-Cof8 immune tolerance induction when combined with rapamycin</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><fpage>1293</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01293</pub-id><pub-id pub-id-type="pmid">32670285</pub-id><pub-id pub-id-type="pmcid">PMC7327091</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>N.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cleaver</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vaught</surname><given-names>L.</given-names></name><name name-style="western"><surname>Falk</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>McCall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>M.</given-names></name></person-group><article-title>Pompe disease gene therapy: Neural manifestations require consideration of CNS directed therapy</article-title><source>Ann. Transl. Med.</source><volume>7</volume><year>2019</year><fpage>290</fpage><pub-id pub-id-type="doi">10.21037/atm.2019.05.56</pub-id><pub-id pub-id-type="pmid">31392202</pub-id><pub-id pub-id-type="pmcid">PMC6642929</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="book" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>C.</given-names></name><name name-style="western"><surname>Glanville</surname><given-names>J.</given-names></name><name name-style="western"><surname>Briscoe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Littlewood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>C.</given-names></name></person-group><part-title>Technical Supplement to Chapter 4: Searching for and selecting studies</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Higgins</surname><given-names>J.P.T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cumpston</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Page</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>V.A.</given-names></name></person-group><source>Cochrane Handbook for Systematic Reviews of Interventions Version 6</source><year>2019</year><publisher-name>Cochrane</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.training.cochrane.org/handbook" id="intref0130">www.training.cochrane.org/handbook</ext-link></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Bowles</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>McPhee</surname><given-names>S.W.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Camp</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Monahan</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Rabinowitz</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector</article-title><source>Mol. Ther.</source><volume>20</volume><year>2012</year><fpage>443</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1038/mt.2011.237</pub-id><pub-id pub-id-type="pmid">22068425</pub-id><pub-id pub-id-type="pmcid">PMC3277234</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Zaidman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Proud</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Goedeker</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Guridi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged &#8805;4 to &lt;8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)</article-title><source>Ann. Neurol.</source><volume>94</volume><year>2023</year><fpage>955</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">37539981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26755</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Leavitt</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Konkle</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Stine</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Visweshwar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Giermasz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Plonski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yver</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study</article-title><source>Blood</source><volume>143</volume><year>2024</year><fpage>796</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1182/blood.2022018971</pub-id><pub-id pub-id-type="pmid">37871576</pub-id><pub-id pub-id-type="pmcid">PMC10933705</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Giermasz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rasko</surname><given-names>J.E.J.</given-names></name><name name-style="western"><surname>Samelson-Jones</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Ducore</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cuker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teitel</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant</article-title><source>N.&#160;Engl. J. Med.</source><volume>377</volume><year>2017</year><fpage>2215</fpage><lpage>2227</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1708538</pub-id><pub-id pub-id-type="pmid">29211678</pub-id><pub-id pub-id-type="pmcid">PMC6029626</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Von Drygalski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giermasz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Castaman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Key</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Lattimore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leebeek</surname><given-names>F.W.G.</given-names></name><name name-style="western"><surname>Miesbach</surname><given-names>W.</given-names></name><name name-style="western"><surname>Recht</surname><given-names>M.</given-names></name><name name-style="western"><surname>Long</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gut</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B</article-title><source>Blood Adv.</source><volume>3</volume><year>2019</year><fpage>3241</fpage><lpage>3247</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000811</pub-id><comment>Erratum in: Blood Adv. 2020 Aug 11;4, :3668. doi: 10.1182/bloodadvances.2020002987</comment><pub-id pub-id-type="pmid">31698454</pub-id><pub-id pub-id-type="pmcid">PMC6855101</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Feuer</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Porciatti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Vanner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guy</surname><given-names>J.</given-names></name></person-group><article-title>Leber Hereditary Optic Neuropathy Gene Therapy: Adverse Events and Visual Acuity Results of All Patient Groups</article-title><source>Am. J. Ophthalmol.</source><volume>241</volume><year>2022</year><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2022.02.023</pub-id><pub-id pub-id-type="pmid">35271811</pub-id><pub-id pub-id-type="pmcid">PMC9444871</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Weleber</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Pennesi</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erker</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>L.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Flotte</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Humphries</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calcedo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy</article-title><source>Ophthalmology</source><volume>123</volume><year>2016</year><fpage>1606</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2016.03.003</pub-id><pub-id pub-id-type="pmid">27102010</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>D'Silva</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kariyawasam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>A.</given-names></name><name name-style="western"><surname>MacLennan</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>H.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy</article-title><source>Ann. Clin. Transl. Neurol.</source><volume>9</volume><year>2022</year><fpage>339</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1002/acn3.51519</pub-id><pub-id pub-id-type="pmid">35170254</pub-id><pub-id pub-id-type="pmcid">PMC8935277</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>von Krusenstiern</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gow</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lotery</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Jalil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>MacLaren</surname><given-names>R.E.</given-names></name><collab>XIRIUS Part 1 Study GroupXOLARIS Study Group</collab></person-group><article-title>Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations</article-title><source>JAMA Ophthalmol.</source><volume>141</volume><year>2023 Mar 1</year><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2022.6254</pub-id><comment>Erratum in: JAMA Ophthalmol. 2023;141:293. doi: 10.1001/jamaophthalmol.2023.0716</comment><pub-id pub-id-type="pmid">36757689</pub-id><pub-id pub-id-type="pmcid">PMC9912164</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Gowda</surname><given-names>V.</given-names></name><name name-style="western"><surname>Atherton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murugan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Standing</surname><given-names>E.</given-names></name><name name-style="western"><surname>Manzur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baranello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Munot</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom</article-title><source>Lancet Reg. Health Eur.</source><volume>37</volume><year>2024</year><fpage>100817</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2023.100817</pub-id><pub-id pub-id-type="pmid">38169987</pub-id><pub-id pub-id-type="pmcid">PMC10758961</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Servais</surname><given-names>L.</given-names></name><name name-style="western"><surname>Day</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Proud</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Tizzano</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Quijano-Roy</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry</article-title><source>J. Neuromuscul. Dis.</source><volume>11</volume><year>2024</year><fpage>425</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.3233/JND-230122</pub-id><pub-id pub-id-type="pmid">38250783</pub-id><pub-id pub-id-type="pmcid">PMC10977451</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Bitetti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lanzara</surname><given-names>V.</given-names></name><name name-style="western"><surname>Margiotta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Varone</surname><given-names>A.</given-names></name></person-group><article-title>Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study</article-title><source>Gene Ther.</source><volume>30</volume><year>2023</year><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1038/s41434-022-00341-6</pub-id><pub-id pub-id-type="pmid">35606491</pub-id><pub-id pub-id-type="pmcid">PMC10457192</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Nanri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yuge</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yae</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mizuochi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Itonaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>Y.</given-names></name></person-group><article-title>Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1</article-title><source>Kurume Med. J.</source><volume>69</volume><year>2024</year><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.2739/kurumemedj.MS6934008</pub-id><pub-id pub-id-type="pmid">38233181</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Witte</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Drube</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haffner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Illsinger</surname><given-names>S.</given-names></name></person-group><article-title>Thrombotische Mikroangiopathie (TMA) nach Genersatztherapie (GRT) bei spinaler Muskelatrophie: Ein Fallbericht und Therapieoption [Thrombotic Microangiopathy (TMA) after Gene Replacemant Therapy (GRT) due to Spinal Muscular Atrophy: Case Summary and Recommendations for Treatment]</article-title><source>Klin. Padiatr.</source><volume>234</volume><year>2022</year><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1055/a-1538-4936</pub-id><comment>German</comment><pub-id pub-id-type="pmid">34388834</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Eisenk&#246;lbl</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#252;hringer</surname><given-names>M.</given-names></name></person-group><article-title>Repeated AAV9 Titer Determination in a Presymptomatic SMA Patient with Three SMN2 Gene Copies - A Case Report</article-title><source>J.&#160;Neuromuscul. Dis.</source><year>2024</year><pub-id pub-id-type="doi">10.3233/JND-221659</pub-id><pub-id pub-id-type="pmcid">PMC10977412</pub-id><pub-id pub-id-type="pmid">38306058</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Favia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tarantino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cerbo</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Sabia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campopiano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pani</surname><given-names>M.</given-names></name></person-group><article-title>Onasemnogene Abeparvovec: Post-infusion Efficacy and Safety in Patients With Spinal Muscular Atrophy (SMA)&#8212;A Fondazione Policlinico Gemelli IRCCS Experience</article-title><source>Hosp. Pharm.</source><volume>59</volume><year>2024</year><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">38223869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00185787231182562</pub-id><pub-id pub-id-type="pmcid">PMC10786062</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Waldrop</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chagat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Storey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reash</surname><given-names>N.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Noritz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Prochoroff</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio</article-title><source>Neuromuscul. Disord.</source><volume>34</volume><year>2024</year><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2023.11.010</pub-id><pub-id pub-id-type="pmid">38142474</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Waldrop</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Karingada</surname><given-names>C.</given-names></name><name name-style="western"><surname>Storey</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>B.</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Noritz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rossman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes</article-title><source>Pediatrics</source><volume>146</volume><year>2020</year><fpage>e20200729</fpage><pub-id pub-id-type="doi">10.1542/peds.2020-0729</pub-id><pub-id pub-id-type="pmid">32843442</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nigro</surname><given-names>E.</given-names></name><name name-style="western"><surname>St-Laurent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weinstock</surname><given-names>L.</given-names></name><name name-style="western"><surname>Law</surname><given-names>E.</given-names></name><name name-style="western"><surname>Janevski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuyntjes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cithiravel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy</article-title><source>Sleep Med.</source><volume>111</volume><year>2023</year><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2023.09.019</pub-id><pub-id pub-id-type="pmid">37778092</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Beri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>L.</given-names></name><name name-style="western"><surname>Parashar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mundada</surname><given-names>V.</given-names></name></person-group><article-title>Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec</article-title><source>Arch. Dis. Child.</source><volume>108</volume><year>2023</year><fpage>866</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2023-325788</pub-id><pub-id pub-id-type="pmid">37553206</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Chencheri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nugud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Majadas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Prudhomme</surname><given-names>K.</given-names></name><name name-style="western"><surname>DeJager</surname><given-names>N.</given-names></name><name name-style="western"><surname>Janardhanan</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Elbashir</surname><given-names>H.</given-names></name></person-group><article-title>Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children</article-title><source>Muscle Nerve</source><volume>68</volume><year>2023</year><fpage>269</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1002/mus.27926</pub-id><pub-id pub-id-type="pmid">37392188</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Soini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wilken</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hell</surname><given-names>A.K.</given-names></name></person-group><article-title>Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec-Preliminary Results</article-title><source>Children (Basel)</source><volume>10</volume><year>2023</year><fpage>998</fpage><pub-id pub-id-type="doi">10.3390/children10060998</pub-id><pub-id pub-id-type="pmid">37371230</pub-id><pub-id pub-id-type="pmcid">PMC10297104</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Pane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coratti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Messina</surname><given-names>S.</given-names></name><name name-style="western"><surname>Catteruccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sframeli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Albamonte</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brolatti</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Italian EAP Working Group. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function</article-title><source>Eur. J. Neurol.</source><volume>30</volume><year>2023</year><fpage>1755</fpage><lpage>1763</lpage><pub-id pub-id-type="doi">10.1111/ene.15768</pub-id><pub-id pub-id-type="pmid">36880698</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Gaillard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Neil Knierbein</surname><given-names>E.E.</given-names></name></person-group><article-title>Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series</article-title><source>J.&#160;Pediatr.</source><volume>260</volume><year>2023</year><fpage>113493</fpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2023.113493</pub-id><pub-id pub-id-type="pmid">37211209</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Tokatly Latzer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sagi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lavi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aharoni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bistritzer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Noyman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ginsburg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lev-Or</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katzenellenbogen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nevo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fattal-Valevski</surname><given-names>A.</given-names></name></person-group><article-title>Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience</article-title><source>Pediatr. Neurol.</source><volume>144</volume><year>2023</year><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2023.04.007</pub-id><pub-id pub-id-type="pmid">37149951</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Sawada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kido</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sugawara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ozasa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fujiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K.</given-names></name></person-group><article-title>Newborn screening for spinal muscular atrophy in Japan: One year of experience</article-title><source>Mol. Genet. Metab. Rep.</source><volume>32</volume><year>2022</year><fpage>100908</fpage><pub-id pub-id-type="doi">10.1016/j.ymgmr.2022.100908</pub-id><pub-id pub-id-type="pmid">35942129</pub-id><pub-id pub-id-type="pmcid">PMC9356196</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Stettner</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Hasselmann</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tscherter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galiart</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jacquier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>A.</given-names></name></person-group><article-title>Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study</article-title><source>BMC Neurol.</source><volume>23</volume><year>2023</year><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/s12883-023-03133-6</pub-id><pub-id pub-id-type="pmid">36855136</pub-id><pub-id pub-id-type="pmcid">PMC9971686</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Tosi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Catteruccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cherchi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mizzoni</surname><given-names>I.</given-names></name><name name-style="western"><surname>D'Amico</surname><given-names>A.</given-names></name></person-group><article-title>Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam</article-title><source>Acta Myol.</source><volume>41</volume><year>2022</year><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.36185/2532-1900-077</pub-id><pub-id pub-id-type="pmid">36349185</pub-id><pub-id pub-id-type="pmcid">PMC9628802</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>J.H.</given-names></name></person-group><article-title>Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy</article-title><source>Brain Dev.</source><volume>44</volume><year>2022</year><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2021.12.006</pub-id><pub-id pub-id-type="pmid">35033405</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Matesanz</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Battista</surname><given-names>V.</given-names></name><name name-style="western"><surname>Flickinger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Kichula</surname><given-names>E.A.</given-names></name></person-group><article-title>Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy</article-title><source>Pediatr. Neurol.</source><volume>118</volume><year>2021</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2021.01.012</pub-id><pub-id pub-id-type="pmid">33677142</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Elsaid</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Abeidah</surname><given-names>M.I.A.</given-names></name><name name-style="western"><surname>Al Rawwas</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Elshafey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Almulla</surname><given-names>H.</given-names></name><name name-style="western"><surname>El-Akouri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Almulla</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Gene therapy for spinal muscular atrophy: the Qatari experience</article-title><source>Gene Ther.</source><volume>28</volume><year>2021</year><fpage>676</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41434-021-00273-7</pub-id><pub-id pub-id-type="pmid">34276047</pub-id><pub-id pub-id-type="pmcid">PMC8599021</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Nevmerzhitskaya</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sapego</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Morozova</surname><given-names>D.A.</given-names></name></person-group><article-title>Short-term safety and efficacy of Onasemnogene Abeparvovec in 10 patients with Spinal Muscular Atrophy: Cohort study</article-title><source>Vopr. Sovr. Pediatr.</source><volume>20</volume><year>2021</year><fpage>589</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.15690/vsp.v20i6s.2367</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Nigro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grunebaum</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>B.</given-names></name><name name-style="western"><surname>Licht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malcolmson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jeewa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>C.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tarnopolsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonorazky</surname><given-names>H.</given-names></name></person-group><article-title>Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment</article-title><source>Front. Neurol.</source><volume>14</volume><year>2023</year><fpage>1230889</fpage><pub-id pub-id-type="doi">10.3389/fneur.2023.1230889</pub-id><pub-id pub-id-type="pmid">37780708</pub-id><pub-id pub-id-type="pmcid">PMC10539898</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Borchert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Nagiel</surname><given-names>A.</given-names></name></person-group><article-title>Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy</article-title><source>Br. J. Ophthalmol.</source><volume>107</volume><year>2023</year><fpage>299</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1136/bjo-2022-321488</pub-id><pub-id pub-id-type="pmid">35835501</pub-id><pub-id pub-id-type="pmcid">PMC9839889</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Jalil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moussa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Parry</surname><given-names>N.R.A.</given-names></name><name name-style="western"><surname>Black</surname><given-names>G.C.M.</given-names></name></person-group><article-title>Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy</article-title><source>Eye</source><volume>37</volume><year>2023</year><fpage>1874</fpage><lpage>1877</lpage><pub-id pub-id-type="doi">10.1038/s41433-022-02262-5</pub-id><pub-id pub-id-type="pmid">36163489</pub-id><pub-id pub-id-type="pmcid">PMC10275908</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Ozelo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Mahlangu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pasi</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Giermasz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Laffan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Symington</surname><given-names>E.</given-names></name><name name-style="western"><surname>Quon</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Peerlinck</surname><given-names>K.</given-names></name><etal/></person-group><article-title>GENEr8-1 Trial Group. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A</article-title><source>N.&#160;Engl. J. Med.</source><volume>386</volume><year>2022</year><fpage>1013</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2113708</pub-id><pub-id pub-id-type="pmid">35294811</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Akl</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><volume>372</volume><year>2021</year><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation></ref></ref-list><sec id="appsec2" sec-type="supplementary-material"><title>Supplemental information</title><p id="p0210">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Document S1. Tables&#160;S1 and S2</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Document S2. Article plus supplemental information</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0185">This project has received funding from the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100010767</institution-id><institution>Innovative Medicines Initiative</institution></institution-wrap></funding-source> 2 Joint Undertaking (JU) under grant agreement no. <award-id award-type="grant" rid="gs1">945473</award-id>. The JU receives support from the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000780</institution-id><institution>European Union</institution></institution-wrap></funding-source> Horizon 2020 research and innovation program and <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100013322</institution-id><institution>EFPIA</institution></institution-wrap></funding-source>. M.A. is also supported by the <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source> grant (ERC Advanced Award no. <award-id award-type="grant" rid="gs4">294745</award-id>), <funding-source id="gs5">MRC</funding-source> DPFS Award (<award-id award-type="grant" rid="gs5">129016</award-id>), <funding-source id="gs6">JPND-MRC</funding-source> (<award-id award-type="grant" rid="gs6">MR/V000470/1</award-id>), <funding-source id="gs7">ARUK</funding-source> award (<award-id award-type="grant" rid="gs7">ARUK-PG2018B-005</award-id>), <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/100012357</institution-id><institution>LifeArc</institution></institution-wrap></funding-source> (No. <award-id award-type="grant" rid="gs8">163978</award-id> and <award-id award-type="grant" rid="gs8">P2022-0004</award-id>, Recipient: <award-id award-type="grant" rid="gs8">176666</award-id>), and MRC/LifeArc award (MR/V030140/1). J.K. is also supported by <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100012357</institution-id><institution>LifeArc</institution></institution-wrap></funding-source>/<funding-source id="gs10">MRC</funding-source>/<funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000268</institution-id><institution>BBSRC</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs11">MR/V030140/1</award-id>) and the <funding-source id="gs12"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000406</institution-id><institution>MND Association</institution></institution-wrap></funding-source> (Kirby/Feb22/969-794). <funding-source id="gs13"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100010767</institution-id><institution>The Innovative Medicines Initiative</institution></institution-wrap></funding-source> (IMI; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://imi-europe.org" id="intref0095">imi-europe.org</ext-link>) and the ARDAT (Accelerating Research&#160;&amp; Development for Advanced Therapies) consortium was formed in 2020 to fund 5 years of research into AAV biology. The overall objective of ARDAT is to develop and provide the data and tools to fill gaps in our knowledge base in the field of immunology and gene therapy and so accelerate the research and development of new AAV therapies for rare diseases.</p><sec id="sec6"><title>Author contributions</title><p id="p0190">B.V., I.S.H., R.H., C.P.W., E.H., F.M., C.B., J.S., M.L., J.E.M., M.D., P.J.S., J.K., M.A., and L.S. conceptualized, designed, extracted data from relevant studies, and assisted with the draft/approval of this manuscript. E.H. carried out a systematic search.</p><p id="p0195">The ARDAT study group also includes Dan Levy, Veres Gabor, Jon Gilbin, Christopher Mann, Francesca Biondo, and Manuela Braun.</p></sec><sec sec-type="COI-statement" id="sec7"><title>Declaration of interests</title><p id="p0200">M.A. is the academic founder and Chief Scientific Officer of BlackfinBio. M.A. is a co-founder of Crucible Therapeutics. L.S. has given lectures/consultancy for Pfizer/RegenexBio/Sarepta/Novartis and Illumina. J.K. has received research funding from Quell Therapeutics.</p></sec></ack><fn-group><fn id="appsec1" fn-type="supplementary-material"><p id="p0205">Supplemental information can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ymthe.2024.07.016" id="intref0100">https://doi.org/10.1016/j.ymthe.2024.07.016</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>